Alivus Life Sciences Limited

Key Highlights

Transaction Details

Alivus Life Sciences Ltd has incorporated a wholly owned subsidiary in Brazil, named 'Alivus Life Sciences Do Brasil Ltda.'. The company will subscribe to 100% of the share capital of the new entity, with a total investment not exceeding R$ 500,000 (Brazilian Reais) in cash.

Regulatory and Compliance

The company confirmed that this incorporation does not fall under the purview of 'Related Party Transactions' as defined by SEBI regulations. The promoter, promoter group, and group companies hold no interest in the newly formed entity. The transaction received necessary approvals from the Federative Republic of Brazil National Registrar of Legal Entities.

Business Context

This development represents a standard expansion of the company's international operations within the pharmaceutical industry. As the entity is newly incorporated, it has no prior turnover history or operational performance metrics to report.

What This Means for Investors

For shareholders, this is a routine procedural update signaling the company's intent to establish or formalize a presence in the Brazilian market. It does not carry immediate financial implications or indicate a material change in near-term revenue or profit profiles. The primary watch point for future updates would be the commencement of commercial operations or specific product registration milestones within the Brazilian market.

Key Highlights

Investor Meeting Details

Alivus Life Sciences Ltd has formally intimated to the stock exchanges its participation in the 'Kotak Healthcare Forum 2026'. The company's representatives are scheduled to engage in group and one-on-one interactions during the event on September 17, 2026, in Mumbai.

Compliance and Disclosure

This filing was made pursuant to Regulation 30 and Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company clarified that the meeting schedule and mode are subject to change due to exigencies on the part of the investors, analysts, or the company itself.

AGM Proceedings Summary

Alivus Life Sciences Ltd (formerly Glenmark Life Sciences Limited) conducted its 15th Annual General Meeting (AGM) on September 8, 2026. The meeting was held via video conferencing (VC)/Other Audio Visual Means (OAVM). All four agenda items were successfully passed by the shareholders with the requisite majority.

Key Business Resolutions

Management Commentary Highlights

During the meeting, the leadership team addressed shareholders with the following updates:

• Financial Performance: Management highlighted a strong financial performance for FY26, citing record profitability and robust cash generation.
• Strategic Growth: The Managing Director outlined the company's 'API+' growth strategy, focusing on expanding advanced pharmaceutical capabilities and continuous investments in manufacturing, R&D, and technology.
• Outlook: The board expressed confidence in long-term value creation, driven by disciplined capital allocation and sustainability initiatives.

Voting Overview

The voting process included both remote e-voting and e-voting conducted during the AGM. Participation was notable, with shareholders casting their votes on all ordinary business and special business items. The appointment of the director (Resolution 3) saw the highest relative opposition, though it still cleared with a significant majority.

Investor Takeaway

The AGM successfully formalized the key corporate actions for the year, most notably the final dividend of Rs 5 per share. The management's commentary underscored a focus on growth via the 'API+' strategy, which existing shareholders should monitor as the company pursues its stated objectives in advanced pharmaceutical capabilities and manufacturing expansion.

Key Highlights

AGM Proceedings

The 15th Annual General Meeting of Alivus Life Sciences Ltd was held on September 8, 2026, through Video Conferencing/Other Audio Visual Means. Mr. Hiren Patel, Chairman & Non-Executive Director, presided over the meeting, which was attended by the directors, CFO, and representatives of the Statutory, Secretarial, Internal, and Cost Auditors. The company confirmed that the notice of the AGM and the Integrated Annual Report for FY 2025-26 were dispatched to members.

Management Commentary

During the meeting, the management team, including the Chairman and the Managing Director & CEO, Dr. Yasir Rawjee, addressed the shareholders:

• Financial Performance: Management emphasized the company's strong performance in FY26, citing revenue growth, record profitability, and strong cash generation.
• Strategic Outlook: Dr. Rawjee outlined the company's future growth strategy, specifically highlighting the "API+" approach. The company intends to continue expanding its advanced pharmaceutical capabilities through investments in manufacturing, R&D, and technology.
• Value Creation: The leadership reiterated a commitment to disciplined capital allocation, sustainability initiatives, and long-term value creation for shareholders.

Resolutions Passed

All four resolutions presented in the AGM notice were passed with the requisite majority by the shareholders:

1. Adoption of Financial Statements: Received, considered, and approved the Audited Financial Statements for the financial year ended 31 March 2026.
2. Dividend Declaration: Declared a final dividend of Rs 5 per equity share for the financial year ended 31 March 2026.
3. Director Appointment: Re-appointed Mr. Hiren Patel (DIN: 00145149) as a Director, retiring by rotation.
4. Cost Auditor Remuneration: Ratified the remuneration payable to the Cost Auditor for the financial year ending 31 March 2027.

Investor Takeaway

The AGM proceedings confirm the successful adoption of the company's FY26 financial accounts and the approval of the proposed dividend payout. Management's forward-looking commentary regarding the "API+" growth strategy and continued capacity investment serves as the primary operational context for the upcoming fiscal year. Existing shareholders should monitor execution progress regarding these identified growth levers in subsequent quarterly updates.

Investor and Analyst Meeting Schedule

Alivus Life Sciences Ltd (formerly Glenmark Life Sciences Limited) has announced the following schedule for upcoming investor and analyst engagements. These meetings are intended to facilitate discussions between company management and representatives from various mutual funds and institutional investors.

Important Notes

• Exigencies: The company has formally notified that the schedule and mode of these meetings remain subject to change due to potential exigencies on the part of the investors, analysts, or the company.
• Regulatory Compliance: This disclosure is made in accordance with Regulation 30 and Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investor and Analyst Meetings

Alivus Life Sciences Ltd has formally intimated the stock exchanges regarding a series of upcoming one-on-one meetings with investors and analysts. These engagements are part of the company's regular investor relations activities.

Meeting Schedule Details

The following table outlines the scheduled meetings as per the filing dated September 5, 2026:

Regulatory Context

This disclosure is provided in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has advised that the schedule and mode of these meetings remain subject to change due to exigencies on the part of the investors, analysts, or the company itself.

Transaction Overview

Alivus Life Sciences Limited has announced the acquisition of a 76% majority stake in IQGenX Pharma Private Limited. The transaction involves a cash consideration of Rs 9.12 crore (INR 91.2 million). The deal is currently subject to customary closing conditions and is expected to conclude by the end of the 2026 calendar year.

Strategic Rationale

This acquisition marks a strategic evolution for Alivus Life Sciences. While the company is a manufacturer of Active Pharmaceutical Ingredients (APIs) for chronic therapeutic areas, this acquisition allows it to:

• Leverage API Portfolio: Integrate its API portfolio into advanced formulation development.
• Expand Capabilities: Add deep scientific expertise in complex delivery formats, including oral solids, complex injectables, and ophthalmics.
• Enhance CDMO Services: Scale its value proposition for global CDMO customers by offering a platform that covers pre-formulation studies, prototype development, process optimization, clinical supplies, and full-scale commercial manufacturing.
• Broaden Service Scope: Incorporate analytical development, methods validation, stability programs, and comprehensive regulatory filing support.

Target Company Profile

Founded in October 2016, IQGenX Pharma Private Limited is a custom research organization. Its operations focus on formulation development for markets in the US, EU, Latin America, Middle East, and other highly regulated and semi-regulated regions.

Integration and Outlook

Alivus intends to leverage IQGenX's specialized platform alongside its existing manufacturing capabilities, with a primary focus on Oncology. The company aims to curate a basket of differentiated, niche assets for strategic out-licensing across multiple geographies.

Company Background

Alivus Life Sciences (formerly Glenmark Life Sciences) manufactures APIs for cardiovascular disease, central nervous system disease, pain management, and diabetes. The company operates four manufacturing facilities in Ankleshwar, Dahej, Mohol, and Kurkumbh, with a total installed capacity of 1,424 KL. Its products are currently supplied to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World.

Key Highlights

Transaction Details

Alivus Life Sciences Ltd (formerly Glenmark Life Sciences Ltd) has entered into a share purchase agreement to acquire a 76% stake in IQGEN-X Pharma Private Limited. The transaction is a cash-based deal with an aggregate consideration of approximately INR 9.12 crore, subject to customary adjustments. The company confirmed that this acquisition does not constitute a related party transaction and no promoter group interests are involved.

About the Target Entity

IQGEN-X Pharma Private Limited, incorporated in 2016, is primarily engaged in formulation development for oral solids, sterile injectables, and ophthalmic solutions for regulated and semi-regulated markets.

Financial Snapshot (Turnover)

• 2025-26: INR 3.48 crore (348 Lacs)
• 2024-25: INR 3.18 crore (318.2 Lacs)
• 2023-24: INR 2.68 crore (267.5 Lacs)

Strategic Rationale

Management stated that the acquisition is designed to provide a wider spectrum of offerings. By integrating IQGEN-X, Alivus aims to provide complete end-to-end solutions to its customers, specifically strengthening its position in the Active Pharmaceutical Ingredients (API) and Contract Development and Manufacturing Organization (CDMO) space.

Concerns and Watch Points

• Completion Conditions: The transaction is subject to the fulfillment of specific conditions precedent outlined in the share purchase agreement.
• Contingency Plan: The filing explicitly notes that if the conditions are not satisfied by the specified timeline, the parties have agreed to enter into a Business Transfer Agreement. This alternative route would involve the company acquiring the entire business of IQGEN-X, including its employees and assets, ensuring the strategic goal remains achievable even if the share purchase structure faces hurdles.

Meeting Schedule

Alivus Life Sciences Ltd has informed the exchanges of upcoming one-on-one meetings with various investors and analysts. The company noted that the schedule and mode of these meetings remain subject to change due to potential exigencies on the part of the participants or the company.

Investor Takeaway

This filing is a standard compliance procedure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains no material financial information or new operational updates.

Publication Details

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has issued a newspaper advertisement regarding the notice of its 15th Annual General Meeting (AGM) and associated e-voting information. The publication serves as compliance under Regulation 47 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Important Dates

Shareholder Instructions

• Meeting Format: The 15th AGM will be held through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
• Annual Report Dispatch: The company has confirmed the dispatch of the Notice of the AGM and the Integrated Annual Report for the Financial Year 2025-26 via email to shareholders.
• E-Voting: Shareholders are provided with a remote e-voting facility to cast their votes on the resolutions proposed at the AGM. Members who have not registered their email addresses are advised to follow the procedures outlined in the notice to obtain login credentials.
• Attendance: Shareholders may join the AGM electronically through the facility provided, with details available on the company's website.

Regulatory Context

This publication is issued in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in compliance with the relevant circulars issued by the Ministry of Corporate Affairs regarding the holding of general meetings via electronic means.

Key Highlights

Sustainability Goals

Alivus Life Sciences has set defined environmental targets to guide its long-term strategy:

• Water Neutrality: Targeted for 2027 through reduction, replenishment, and harvesting projects.
• Carbon Neutrality: Targeted for 2030 via energy efficiency, renewable energy adoption, and carbon sequestration.

Environmental Performance

Concerns and Watch Points

Environmental Incident

On September 30, 2025, a flash fire occurred at Unit No. 6 of the Ankleshwar Plant. As a result, the Gujarat Pollution Control Board (GPCB) imposed an Environmental Damage Compensation of ₹29 lakh (converted from the reported figure) and requested a Bank Guarantee of ₹10 lakh (converted from the reported figure) as compliance assurance. The company has confirmed that necessary corrective and preventive measures have been implemented, and no material impact on operations or financials was observed.

Corporate Governance and ESG

The company has demonstrated a proactive approach to governance by establishing an ESG Committee under the Board's direction. Independent limited assurance on its BRSR Core KPIs for FY 2025-26 was provided by the British Standards Institution (BSI), reinforcing the credibility of its sustainability disclosures.

Investor Takeaway

Alivus Life Sciences continues to focus on its core API manufacturing business while progressively integrating ESG principles into its operations. The company's transparency regarding the Ankleshwar plant incident and its ongoing efforts toward water and carbon neutrality are key areas for investors to track. The reliance on export markets (54.4% of turnover) makes operational continuity and regulatory compliance in its manufacturing units critical for sustained performance. Investors should continue monitoring the company’s progress toward its 2027 and 2030 sustainability objectives.

Key Highlights

Financial Snapshot

Financial Performance

Alivus Life Sciences demonstrated robust financial health in FY26. Revenue from operations increased to ₹2,551.83 crore, a 6.9% growth year-on-year. The net profit after tax reached ₹564.48 crore. The company maintains a net debt-free balance sheet, funded entirely by internal accruals, providing substantial flexibility for future growth investments. An EBITDA margin of 33.6% was achieved, marking a 360 basis-point expansion.

Business and Operations

Management highlighted the success of the 'API+' strategy, which focuses on adjacent capabilities such as flow chemistry, high-potent APIs (HPAPI), and pellets. The CDMO business has emerged as a key growth driver, recording an 18% YoY growth in FY26. To support these initiatives, the company continues to invest in manufacturing infrastructure, with a total reactor capacity of 1,424 KL in FY26 and plans to reach 2,690 KL by FY29.

Strategic Developments

Planned capital expenditure for FY27 is estimated at ₹540 crore. This investment will focus on a new R&D facility in Taloja and a greenfield project in Solapur, fully funded by internal cash flows.

Corporate Action

The Board has recommended a final dividend of 250%, which amounts to ₹5 per equity share of face value ₹2 each for FY26.

Concerns and Watch Points

Investor Takeaway

Alivus Life Sciences continues to show consistent growth with strong cash flow generation and margin improvements. The company's 'API+' strategy and expansion into high-value segments like CDMO appear to be yielding positive results. Investors should monitor the progress of the Solapur and Dahej capacity expansion projects, as well as the company’s ability to navigate potential global regulatory and pricing headwinds.

Key Highlights

Corporate Action Details

The Board of Directors of Alivus Life Sciences Limited has recommended a final dividend of ₹5 per equity share for the financial year ended March 31, 2026. The company has set Tuesday, September 1, 2026, as the record date to determine the list of members eligible for the dividend payout. The payment will be subject to approval by shareholders at the upcoming 15th Annual General Meeting (AGM).

Board Decision or Meeting Update

• AGM Logistics: The 15th AGM is scheduled for September 8, 2026, at 3:00 p.m. IST. Due to current regulations, the meeting will be held through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
• Director Re-appointment: Mr. Hiren Patel, a Non-Executive Director, is proposed for re-appointment. He has been associated with the company since March 6, 2024, and the board believes his leadership and expertise in the healthcare, chemical, and consumer goods industries continue to benefit the company.
• Cost Auditor Ratification: The board has proposed the ratification of Kirit Mehta & Co. LLP as cost auditors for the financial year ending March 31, 2027, with a remuneration of ₹0.05 crore (₹5 lakh) plus applicable taxes and expenses.

What This Means for Investors

This update outlines the standard annual procedures for Alivus Life Sciences Limited. Investors should track the record date (September 1, 2026) to ensure eligibility for the declared dividend. Shareholders are also encouraged to participate in the remote e-voting process, which is open from September 4, 2026, to September 7, 2026, to vote on the proposed resolutions.

Investor Takeaway

The notice provides standard procedural information regarding the upcoming AGM. The primary interest for existing shareholders is the dividend recommendation and the re-appointment of leadership. Investors should ensure their PAN and bank details are updated with their depository participants to facilitate smooth dividend credit and tax compliance. No significant risks or operational disruptions were indicated in this notice.

Meeting Details

Alivus Life Sciences Ltd has disclosed the following details regarding its upcoming investor engagement:

Corporate Context

The company has noted that this meeting may be subject to changes due to potential exigencies on the part of the investor or the company itself.

Alivus Life Sciences Ltd, formerly identified as Glenmark Life Sciences Limited, issued this disclosure pursuant to Regulation 30 and Para A of Part A of Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Meeting Details

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced that it will participate in an upcoming investor and analyst interaction.

Meeting Note

The company clarified that the schedule and mode of the meeting are subject to change due to exigencies on the part of the Investor, Analyst, or the Company. This disclosure is made in compliance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Key Highlights

Financial Snapshot

Revenue and Income Analysis

The company's revenue for the quarter stood at ₹640 crore. A notable trend in Q1 FY '27 was the performance divergence between segments. The GPL business experienced a significant decline of 52.6% YoY, attributed to inventory rationalization. This was effectively offset by the non-GPL business, which recorded robust growth of 26.5% YoY, driven by new product launches and sustained demand across geographies.

Profitability Analysis

Profitability metrics showed strong improvement. Gross profit reached ₹385 crore with a 60.2% margin, reflecting a 510 basis point improvement YoY. EBITDA stood at ₹234 crore, with margins at 36.6%, marking a 650 basis point YoY increase. This performance highlights disciplined operational execution and favorable product mix. The Profit After Tax (PAT) for the quarter was ₹160 crore, maintaining a margin of 25%.

Management Commentary and Outlook

Management has provided a revenue growth guidance of 10-12% for FY '27, with a skew expected towards the second half of the year. EBITDA margins are projected to be sustainable in the 30-32% range, with a potential to touch 34% in steady-state conditions. This conservative guidance accounts for global geopolitical conflicts and potential raw material price volatility.

Capacity Expansion

The Solapur facility is seeing a slight delay but is expected to be operational by early Q3 FY '27. Management is prioritizing regulatory audits for this facility post-commencement to open up access to regulated markets. Expansion work at Ankleshwar (110KL) and Dahej (160KL) remains on track.

What Looks Positive

• Volume-Led Growth: The 26.5% growth in the non-GPL segment was primarily driven by 21-22% volume growth, signaling strong market demand.
• Operational Efficiency: EBITDA margin improvement of 650 basis points and Gross margin improvement of 510 basis points indicate successful cost management and efficiency gains.
• Strong Balance Sheet: The company remains debt-free with cash and cash equivalents, including short-term investments, totaling ₹880 crore.

Concerns and Watch Points

• GPL Business Performance: The 52.6% YoY decline is significant. While management expects this segment to remain flattish for the full year, investors should monitor for sustained weakness.
• Geopolitical Volatility: Global conflicts are impacting raw material and solvent costs. While the company is passing on some costs to customers, prolonged volatility poses a risk to margin stability.

Investor Takeaway

Alivus Life Sciences successfully navigated a challenging quarter in its GPL segment through strong performance in its non-GPL and CDMO portfolios. The company's focus on operational efficiency and volume-driven growth has resulted in expanded margins. Investors should watch the commissioning of the Solapur facility, the recovery trajectory of the GPL business in the second half of the year, and the company's ability to manage raw material cost pressures given the current geopolitical environment.

AGM and Meeting Details

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has officially announced the schedule for its 15th Annual General Meeting (AGM). The meeting is slated for Tuesday, September 8, 2026, at 3:00 p.m. IST. In line with regulatory requirements, the meeting will be conducted via Video Conferencing (VC) or Other Audio Visual Means (OAVM).

Dividend and Record Date

The company has set August 24, 2026, as the record date for determining the eligibility of shareholders to receive the final dividend for the financial year. Shareholders who are listed in the company's register or the depository records as of this date will be eligible for the payment. Subject to shareholder approval at the AGM, the dividend is scheduled to be distributed on or after September 22, 2026.

E-Voting and Shareholder Participation

The company has provided comprehensive details regarding e-voting procedures, allowing shareholders to exercise their voting rights electronically. Shareholders who have not yet registered their email addresses with the company or their respective depository participants are advised to do so immediately. This ensures they receive the annual report and the necessary credentials to access the virtual meeting platform.

Regulatory Compliance

This public notice was issued in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The advertisement was published in the Financial Express (English, All India edition) and Loksatta (Marathi) on August 6, 2026, to ensure widespread notification to all stakeholders.

Key Highlights

Corporate Action Details

The company has confirmed the timeline for the final dividend for the financial year ended March 31, 2026. The Board had previously recommended a dividend of ₹5.00 per equity share (face value of ₹2.00). The payment of this dividend is subject to approval by shareholders at the upcoming Annual General Meeting.

Board Decision or Meeting Update

The 15th Annual General Meeting is scheduled for September 8, 2026, at 03:00 pm (IST) via Video Conferencing or Other Audio-Visual Means, as per the relevant circulars from the Ministry of Corporate Affairs and SEBI.

Investor Takeaway

Shareholders should note September 1, 2026, as the record date. Investors must hold the shares on this date to be eligible for the dividend payout. The company has clarified that the dividend payment will be subject to tax deduction at source (TDS). This is a routine procedural update, and no material strategic shifts or surprises are implied in this filing.

Key Highlights

Corporate Action Details

The company has confirmed the timeline for the final dividend for the financial year ended March 31, 2026. The Board of Directors had previously recommended a dividend of Rs. 5.00 per equity share with a face value of Rs. 2. The distribution is subject to approval by shareholders at the upcoming 15th Annual General Meeting.

For investors, the record date of September 1, 2026, is the critical cut-off. Beneficial owners as of the close of business hours on this date will be eligible to receive the dividend. Payment is expected to commence on or after September 11, 2026, subject to applicable tax deductions at source (TDS).

Board Decision and Meeting Update

The 15th Annual General Meeting is scheduled for September 8, 2026, at 03:00 PM (IST). In line with regulatory permissions, the meeting will be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM).

Investor Takeaway

This filing confirms the procedural timeline for the final dividend distribution and the scheduling of the company's 15th AGM. Shareholders should mark September 1, 2026, as the key record date for dividend eligibility. As the dividend is subject to shareholder approval, the AGM serves as the final step before the payout scheduled for mid-September. No strategic surprises were noted in this routine compliance update.

Earnings Call Recording

Alivus Life Sciences Limited has fulfilled its regulatory obligation to provide public access to its earnings call audio recording. The recording pertains to the Q1 FY2027 earnings call held on July 31, 2026.

Investor Relevance

This update allows shareholders and interested parties to review the management's discussion, including strategic commentary and insights shared during the Q&A segment of the recent earnings call. The audio file is hosted on the company's official website.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates that companies provide audio or video recordings of earnings calls to ensure transparency and equitable access to information for all stakeholders.

Key Highlights

Alivus Life Sciences Limited has allotted 32,000 equity shares to eligible employees. This allotment was executed under the 'Employee Stock Option Scheme, 2021' as approved by the Board of Directors on July 30, 2026.

Important Figures Used

Financial Snapshot

Following the exercise of stock options by employees, the company’s paid-up share capital has increased.

Investor Takeaway

This announcement pertains to the standard exercise of Employee Stock Options (ESOPs) and is a routine administrative process. It does not indicate any change in business strategy, financial performance, or market fundamentals. Existing shareholders should view this as a standard corporate housekeeping event regarding capital structure adjustments.

Key Highlights

Financial Snapshot

Revenue and Income Analysis

Revenue from operations reached ₹ 6,404 million for the quarter ended June 30, 2026. While the company achieved a 6.4% year-on-year growth, revenue declined 7.1% sequentially compared to Q4 FY26. The growth performance was primarily supported by the non-GPL business, which saw a 26.5% year-on-year and 27.6% quarter-on-quarter increase.

Profitability Analysis

Profitability metrics showed significant improvement compared to the same period last year. EBITDA grew by 29.1% year-on-year, and PAT increased by 31.8% year-on-year, reaching ₹ 1,601 million. These figures indicate a strong bottom-line performance despite top-line volatility.

Margin Analysis

Operational efficiency was a key highlight, with the EBITDA margin expanding to 36.6% from 30.1% in Q1 FY26 (a 650 bps increase). Net margin also improved significantly, reaching 25.0% compared to 20.2% in the previous year's corresponding quarter.

Segment Performance

The performance divergence between segments was notable. The non-GPL portfolio grew strongly, while the GPL segment faced a 52.6% year-on-year de-growth, attributed by management to inventory rationalization. The company anticipates this GPL business to remain flattish for the full fiscal year.

Management Outlook

Management has provided clear financial guidance for FY27, expecting overall revenue growth in the range of 10-12% and EBITDA margins to be sustained between 30% and 32%. They noted that the GPL business is historically skewed towards the second half of the fiscal year.

Balance Sheet and Cash Flow

The company maintains a robust financial position, generating ₹ 901 million in free cash flow during the quarter. As of June 30, 2026, the company held ₹ 8,802 million in cash and cash equivalents, including short-term investments.

What Looks Positive

• Margin Expansion: Significant year-on-year improvement in both EBITDA and net margins.
• Cash Position: Strong free cash flow generation and healthy cash reserves provide flexibility for future capital requirements.
• Non-GPL Growth: Strong double-digit growth in non-GPL operations suggests underlying demand remains solid.

Concerns and Watch Points

• GPL Business Decline: The significant year-on-year decline in the GPL segment is a point for investors to watch as the company monitors recovery.
• Sequential Revenue Dip: Revenue declined 7.1% sequentially, highlighting potential volatility in short-term demand patterns.

What This Means for Investors

The results reflect a period of operational focus and margin improvement for Alivus Life Sciences. While the GPL business remains a drag in the short term, the company's strong non-GPL growth, combined with positive guidance and significant cash reserves, suggests a stable trajectory. Investors should closely monitor the recovery of the GPL segment in H2 and the progress of ongoing capacity expansion projects.

Investor Takeaway

Alivus Life Sciences delivered a quarter marked by strong profitability and margin resilience. The contrast between robust non-GPL growth and the inventory-related weakness in the GPL segment remains the key operational theme. With clear guidance for FY27 and a strong balance sheet, the company appears positioned to manage its planned capital expenditure while navigating market uncertainties.

Key Highlights

Financial Snapshot

Financial Performance

The company reported resilient performance in Q1 FY27. Revenue from operations reached ₹640.4 crore, growing 6.4% YoY. Profitability saw robust expansion, with EBITDA rising 29.1% YoY to ₹234.1 crore. The company achieved its highest-ever EBITDA margin of 36.6%. Consequently, Profit After Tax (PAT) grew 31.8% YoY to ₹160.1 crore, with margins improving to 25.0%.

Segment Performance

The revenue growth trajectory was significantly supported by the non-GPL business, which delivered a 26.5% YoY growth. In contrast, the GPL business experienced a significant decline during the quarter. Management expects the GPL business to remain flattish for the full fiscal year FY27, citing a historical skew toward the second half of the year.

Balance Sheet and Cash Flow

As of June 30, 2026, the company maintained a healthy liquidity position with cash and cash equivalents (including short-term investments) of ₹880.2 crore. The company remains net debt-free. During the quarter, it generated a free cash flow of ₹90.1 crore.

Capex and R&D Updates

• Manufacturing Expansion: Construction is ongoing for Solapur Phase 1 (350 KL capacity) and Phase 2 (115 KL capacity), with completion expected in Q3 FY27 and Q4 FY27, respectively.
• R&D Initiatives: Construction has commenced on a new R&D facility in Taloja, Navi Mumbai. This center is designed to focus on flow chemistry, complex products, oncology, particle engineering, and green chemistry.

Guidance for FY27

Management has provided the following outlook for the financial year 2027:

• Revenue Growth: Targeted at 10%–12%.
• EBITDA Margins: Expected to be sustained in the 30%–32% range.

Investor Takeaway

Alivus Life Sciences demonstrated a strong start to the fiscal year with significant margin expansion and bottom-line growth, primarily driven by the non-GPL segment. The company's net debt-free status and cash generation provide a solid foundation for its ongoing capex plans in Solapur and R&D investments in Taloja. While the non-GPL business acts as a strong growth engine, investors should monitor the performance of the GPL segment, which management expects to remain flat for FY27, and track the timely commissioning of the new manufacturing and R&D capacities.

Financial Snapshot

Key Highlights

• Financial Performance: The company posted a net profit of ₹160.08 crore (₹16007.6 lakh) for the quarter ended June 30, 2026, compared to ₹121.54 crore (₹12153.5 lakh) in the corresponding quarter of the previous year.
• Revenue: Revenue from operations reached ₹640.41 crore (₹64041.4 lakh) for the current quarter, up from ₹601.85 crore (₹60184.6 lakh) in the year-ago period.
• Earnings per Share: Basic EPS for the quarter was ₹13.04, while Diluted EPS was ₹13.01.

Corporate Identity Change

The company is now officially operating as Alivus Life Sciences Limited (formerly known as Glenmark Life Sciences Limited). Investors should take note of this name change for tracking corporate filings and branding updates.

Business and Operations

The company operates with a focus on the Active Pharmaceutical Ingredient (API) segment. It identified this as the sole reporting segment for the quarter, indicating a high concentration of business activity in the API market.

Management and Compliance

The financial results for the quarter ended June 30, 2026, were reviewed by the Audit Committee and approved by the Board on July 30, 2026. The statutory auditors, Walker Chandiok & Co LLP, issued an unmodified review conclusion, confirming that the results were prepared in accordance with Ind AS standards.

Corporate Actions

During the quarter ended June 30, 2026, the company allotted 3,100 equity shares under the Employee Stock Option Scheme 2021. This resulted in an increase in the paid-up equity share capital to ₹24.55 crore (₹2454.8 lakh).

What Looks Positive

• Growth Trend: Both top-line revenue and bottom-line net profit showed year-over-year improvement.
• Compliance: The results were issued with an unmodified auditor review, providing assurance on financial integrity.

Watch Points

• Segment Concentration: The company relies solely on the API segment. Investors should monitor developments in this specific sector as the company's financial results are highly sensitive to API market dynamics.

What This Means for Investors

The company has delivered a stable quarter with year-over-year growth in both revenue and profitability. The focus remains on the API segment. The primary change is the corporate identity, which investors should track for future communications. The results are compliant and reviewed by auditors, presenting no immediate governance concerns.

Key Highlights

Financial Snapshot

Revenue and Income Analysis

Alivus Life Sciences achieved consolidated revenue from operations of 6,404.14 million for the quarter ended June 30, 2026, marking a 6.41% increase compared to the 6,018.46 million recorded in the same quarter last year. Total income for the period reached 6,628.15 million.

Profitability Analysis

The company delivered a strong bottom-line performance, with net profit rising to 1,600.76 million from 1,215.35 million in the corresponding quarter of the previous year. This reflects a significant year-over-year improvement in profitability. Basic earnings per share (EPS) stood at 13.04, compared to 9.91 in the prior-year period.

Corporate Action Details

The company confirmed its name transition to 'Alivus Life Sciences Limited' (formerly Glenmark Life Sciences Limited). Additionally, paid-up equity share capital increased to 245.48 million following the allotment of 3,100 equity shares under the Employee Stock Option Plan 2021.

What Looks Positive

• Earnings Growth: Both revenue and net profit showed year-over-year growth, indicating sustained operational performance.
• Audit Status: The statutory auditors expressed an unmodified review conclusion, indicating no material concerns in the reported financials.

What This Means for Investors

The results highlight consistent growth in the company's core API business. The transition to the new corporate identity and the continued execution of ESOP plans are standard developments for investors to track. The absence of audit concerns provides a stable foundation for the reported figures.

Investor Takeaway

Alivus Life Sciences delivered a positive quarter with measurable top-line and bottom-line growth on a year-over-year basis. The company maintains its focus on the API segment with an unmodified auditor review. Investors should monitor ongoing operational performance and any further impact of the recent corporate identity transition on the business outlook.

Earnings Call Details

Alivus Life Sciences Ltd (formerly Glenmark Life Sciences Ltd) has scheduled its earnings conference call to review the financial performance for the quarter ended Q1 FY2026-27. Management will provide updates on the company's operational and financial standing during this session.

Access and Participation

The company has established dial-in options to facilitate broad participation from institutional and retail investors. Universal dial-in numbers (+91 22 6280 1564 and +91 22 7115 8394) are available for domestic callers. Additionally, international toll-free and toll numbers have been provided for participants in Australia, Canada, China, Hong Kong, Italy, Japan, Singapore, South Korea, South Africa, the UK, and the USA.

Participants are advised to pre-register online to ensure access to the call.

Investor Relations Contacts

For any clarifications regarding the earnings call or the company’s disclosures, investors may contact the following representatives:

• Diwakar Pingle: Diwakar.Pingle@in.ey.com
• Runjhun Jain: Runjhun.Jain1@in.ey.com

Investor Takeaway

This filing serves as a routine intimation of the upcoming Q1 FY2026-27 earnings conference call. Existing shareholders and interested investors should note the scheduled date and time to track management commentary on the company's quarterly results. The provision of international connectivity reflects efforts to ensure accessibility for a global investor base. No financial results were disclosed in this notice.

Board Meeting Update

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has officially notified the stock exchanges regarding the scheduling of a Board of Directors meeting. The meeting is set to take place on Thursday, July 30, 2026.

The agenda for this meeting includes the consideration and approval of the company's unaudited financial results for the quarter ended June 30, 2026. This meeting is convened pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Trading Window Closure

In alignment with the Code of Conduct for the Prevention of Insider Trading, the company has implemented a closure of its trading window. The window is closed for designated persons starting from July 1, 2026, and will remain closed until August 1, 2026 (both days inclusive). This is a mandatory regulatory compliance procedure observed by listed companies to prevent trading during the period when unpublished price-sensitive information is being finalized.

What This Means for Investors

This announcement is a routine procedural update notifying the market of the upcoming date for the Q1 financial results. Investors should mark July 30, 2026, as the key date for the release of the company's financial performance. No financial data has been released at this stage. The trading window closure is a standard governance practice and does not imply any specific operational issues.

Board Meeting Announcement

Alivus Life Sciences Limited has formally notified the stock exchanges that a meeting of its Board of Directors is scheduled for Thursday, July 30, 2026. The agenda for this meeting includes the consideration and approval of the company's unaudited financial results for the quarter ended June 30, 2026.

Trading Window Closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, the trading window for designated persons has been closed. This restriction period is effective from July 1, 2026, through August 1, 2026 (both days inclusive). The window closure is a standard procedure undertaken prior to the release of financial results to prevent insider trading.

Corporate Identity

The company filing notes that it is formally recognized as Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited.

Summary

• Alivus Life Sciences has received a tax demand order from the Income Tax Department.
• The demand for AY 2023-24 is ₹260.68 lakh (₹2.61 crore) including interest, due to expenditure disallowances.
• The company reports no material impact on financial operations and will evaluate its right to appeal.

Key Numbers & Dates

• Tax Demand (including interest): ₹2,60,67,810 (₹260.68 lakh / ₹2.61 cr)
• Assessment Year (AY): 2023-24
• Financial Year (FY): 2022-23
• Order Date: March 20, 2026
• Receipt Date: March 20, 2026, around 7:30 PM

What Changes for the Business

• The company has been issued an assessment order by the Income Tax Department.
• The company asserts no material impact on its financial performance or operations.
• The company reserves the right to appeal the order.

⚠️ What Could Go Wrong (source-based)

• [Financial] A tax demand of ₹2.61 crore has been raised, which is currently appealable.

What to Track Next

• The company will conduct an assessment to determine if it will exercise its right to appeal the tax order.

Summary

• Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced details of an upcoming analyst and institutional investor meeting.
• The meeting is scheduled to take place on March 17, 2026.
• It will be an in-person meeting held in Mumbai with Millennium Capital Management.
• The company noted that the schedule and mode of the meeting may be subject to change due to unforeseen circumstances.

Key Numbers & Dates

• Announcement Date: March 12, 2026
• Analyst/Investor Meeting Date: March 17, 2026

⚠️ What Could Go Wrong (source-based)

• [Other] The schedule and mode of the meeting may undergo a change due to exigencies on the part of the Investor/Analyst/Company.

Summary

• Alivus Life Sciences Limited has disclosed details of upcoming meetings scheduled with analysts and institutional investors.
• These meetings are planned to take place in March 2026.

Key Numbers & Dates

• March 12, 2026: Virtual one-on-one meeting with ICICI Direct.
• March 16, 2026: In-person one-on-one meetings with Green Lantern Capital and S Four Capital in Mumbai.

What Could Go Wrong (source-based)

• [Execution] The schedule and mode of meetings may change due to exigencies on the part of the investor, analyst, or the company.

What to Track Next

• Monitor the company's schedule for any potential changes to the announced investor/analyst meetings.

Summary

• Alivus Life Sciences disclosed an update on a fire incident at its Dahej, Gujarat facility on February 14, 2026.
• The fire affected one production block's intermediate manufacturing facilities, while API facilities in that block and all other six blocks remain operational.
• The company expects to resume API production from March 1, 2026, and intermediate production by mid-March 2026.
• This incident may lead to a few delayed shipments.

Key Numbers & Dates

• Total production blocks at Dahej facility: 7
• Production blocks affected by fire: 1
• Production blocks remaining fully operational: 6
• Date of fire incident: February 14, 2026
• Expected resumption of API production: March 1, 2026
• Expected resumption of intermediate production: Mid-March 2026

What Changes for the Business

• Temporary halt in intermediate manufacturing at one block.
• Potential for a few delayed shipments due to the disruption.

⚠️ What Could Go Wrong (source-based)

• [Execution] Delayed shipments may occur due to the temporary cessation of manufacturing operations.

What to Track Next

• Monitor the actual resumption of API and intermediate production by the stated mid-March 2026 timeline.
• Assess the extent and duration of any 'delayed shipments'.

News Crux

A fire broke out at Alivus Life Sciences' Dahej API plant on February 14, 2026, resulting in three injuries and a temporary suspension of operations.

⚠️ Investor Risks & Governance

• [Operational Risk] Fire incident at Dahej API plant on February 14, 2026, resulted in three injuries.
• [Operational Risk] Production/Operations of the Dahej API factory are temporarily suspended.
• [Financial Risk] The company is currently ascertaining the quantum of loss/damage caused by the fire.

Key Events

• A fire occurred at Alivus Life Sciences Limited's API Plant located at Z-103/I, SEZ, Phase II, District Bharuch, Dahej - 392 130, Gujarat, India on February 14, 2026.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, has announced its participation in upcoming investor and analyst meetings throughout February 2026. The company's representatives will attend three key industry conferences held in Mumbai: the MANTHAN - Systematix India Annual Conference on February 10, 2026, the Nuvama India Conference 2026 on February 11, 2026, and the Kotak Conference - CHASING GROWTH 2026 on February 26, 2026. These interactions will take the form of group sessions and one-on-one meetings. The company has also noted that the schedule is subject to potential changes due to exigencies from the investors, analysts, or the company itself. This disclosure is an intimation of engagement opportunities and does not contain any specific financial results, performance analysis, management guidance, or outlook.

News Crux & Q3 FY'26 Performance

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) held its Q3 FY'26 earnings call on January 22, 2026, reporting a robust financial performance. The company achieved its highest-ever quarterly revenue of Rs. 673 crores, marking a 4.8% year-on-year (YoY) and 14.4% quarter-on-quarter (QoQ) growth. This strong top-line performance was complemented by significant improvements in profitability, with EBITDA margins reaching an all-time high of 36.4% for the quarter, a substantial increase of 510 basis points YoY and 340 bps QoQ. Gross margins also saw a healthy rise to 58.9%. Profit After Tax (PAT) for the quarter stood at Rs. 150 crores.

9-Months FY'26 Performance and Financials

For the nine months ended December 31, 2025, Alivus Life Sciences reported revenue of Rs. 1,863 crores, a 7.2% YoY growth. The company's EBITDA for the nine-month period was Rs. 620 crores, up 22% YoY, with an EBITDA margin of 33.3% (up 400 bps YoY). PAT for the nine months was Rs. 402 crores, with margins at 21.6%. The company continues to be net debt-free and reported a strong free cash flow generation of Rs. 221 crores for the nine-month period, with cash and cash equivalents standing at Rs. 733 crores as of December 31, 2025. R&D expenditure for Q3 FY'26 was Rs. 23 crores (3.4% of sales).

Outlook, Guidance, and Concall Commentary

Management provided a positive outlook, raising the EBITDA margin guidance for the future to a range of 30%-32%, up from the earlier 28%-30%, driven by operational efficiencies, new product launches, and a favorable product mix. The company expects high single-digit revenue growth for FY'26 and FY'27, with expectations of achieving double-digit growth from FY'28-'29. Capital expenditure (CAPEX) for FY'26 has been revised downwards to around Rs. 450 crores, with Rs. 150 crores deferred to FY'27, compared to the earlier guidance of Rs. 600 crores. The Solapur expansion project is now expected to commence operations by July 2026, facing a slight delay of approximately three months. However, brownfield expansions at Ankleshwar and Dahej are progressing as planned and are anticipated to become operational in Q2 FY'27. The CDMO segment, a key driver, is showing strong recovery and growth, with management confident in adding 1-2 new projects by Q1 FY'27.

Financial Deep Dive and Key Events

The company's financial health remains strong, maintaining its net debt-free status. CAPEX for Q3 FY'26 was Rs. 105 crores, and Rs. 218 crores for the nine months. While the Solapur capacity expansion faced a slight delay and a recalibration in planned capacity, management emphasized that this is a calibrated approach based on product mapping to avoid under-utilization. Expansions at Ankleshwar and Dahej are critical for servicing regulated markets for the next couple of years. The company is also investing in R&D capabilities, focusing on flow chemistry and green chemistry to enhance productivity and explore new business opportunities. The high-potent API portfolio is on track for development.

Long-Term Direction and Risks

Alivus Life Sciences anticipates a long-term encouraging outlook for the global pharma industry, driven by factors like an aging population and rising chronic disease prevalence. The company's strategy centers on maintaining a high-quality business that generates cash, with careful deployment of capital for inorganic expansion when the right opportunities arise. While the geopolitical situation poses a general risk for international businesses, the company's diversified geographic presence helps mitigate significant impact. Pricing erosion is a known factor, but managed through next-generation processes. The company is focused on leveraging its strengths in API generics and CDMO services for sustainable growth.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has disclosed an intimation received from the Office of the Joint Commissioner of State Tax (Appeals), Goods and Service Tax, Solapur. This disclosure, made under SEBI Listing Regulations, pertains to an order passed under Section 107(11) of the Maharashtra Goods & Service Tax Act, 2017, dated January 29, 2026.

The order relates to a previous demand passed by the State Goods and Service Tax department for the Financial Year 2019-20 under Section 73(9). The original demand was for Rs. 5,21,51,441, along with a penalty of Rs. 52,15,155 and applicable interest. Following an appeal filed by the company, the first appellate authorities have granted partial relief. The revised demand has been reduced to Rs. 83,38,062, with a penalty amounting to Rs. 8,33,806 and applicable interest.

The company has stated that there is no material impact on its financial, operational, or other activities due to this tax payable intimation. The order is currently appealable before the tribunal, and Alivus Life Sciences Limited will assess its right to appeal further. The company received this intimation around 6:00 PM on January 29, 2026.

Alivus Life Sciences Limited, previously known as Glenmark Life Sciences Limited, has submitted a disclosure to the stock exchanges regarding upcoming meetings with investors and analysts. These engagements are scheduled to take place over a three-day period, from February 2nd to February 4th, 2026.

The company has organized one-on-one meetings with several financial entities. These include Catamaran, Vyom Partners, Choice India, and Avendus Spark, all of which will be virtual meetings. Kosh Wealth Management is also scheduled for a one-on-one meeting, which will be conducted in-person in Mumbai.

Alivus Life Sciences has cautioned that the announced schedule, including the mode of meeting, may be subject to change due to exigencies on the part of the investors, analysts, or the company. This intimation is made in compliance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The announcement does not contain any financial results, performance updates, or specific future guidance.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, has issued a regulatory filing on January 22, 2026. The company formally announced the upload of the audio recording of its Q3 FY2025-26 Earnings Call. This action is in compliance with Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing directs investors to the official website of Alivus Life Sciences Limited, where the complete audio recording of the earnings call is now accessible. The URL provided for the recording is https://www.alivus.com/alivus_pdfs/investors/financials/reports_presentation/10039101.mp3. This disclosure serves to inform the stock exchanges, namely BSE Ltd. and National Stock Exchange of India Ltd., and subsequently the investing public, about the availability of this crucial communication channel. Earnings calls typically offer detailed insights into a company's quarterly financial performance, operational updates, strategic initiatives, and future outlook as discussed by the management. However, this particular announcement from Alivus Life Sciences Limited solely confirms the availability of the call's audio playback and does not include the specific financial figures, results, guidance, or any in-depth discussion points that were presented during the call itself. Investors seeking details on the company's performance or outlook for Q3 FY2025-26 would need to access the provided audio recording.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, released its Investor Presentation for Q3 FY25-26, detailing a period of significant operational improvement and financial growth. The company reported revenue from operations of ₹6,729 million for Q3 FY26, marking a robust 14.4% quarter-on-quarter (QoQ) and a healthy 4.8% year-on-year (YoY) increase. This performance was primarily driven by a strong recovery in the CDMO (Contract Development and Manufacturing Organization) segment, fueled by new project contributions and sustained growth momentum in regulated markets. For the first nine months of FY26 (9MFY26), revenues reached ₹18,627 million, a 7.2% YoY growth.

Profitability metrics saw substantial improvements. Gross Margins stood at 58.9% in Q3 FY26, up by 120 bps QoQ and 330 bps YoY, attributed to new product launches, product mix optimization, and operational efficiencies. EBITDA Margins for the quarter were a strong 36.4%, an impressive increase of 340 bps QoQ and 510 bps YoY. For 9MFY26, EBITDA margins were 33.3%, showing a 400 bps YoY improvement. Profit After Tax (PAT) for Q3 FY26 was ₹1,503 million, a 9.7% increase YoY, and for 9MFY26, PAT grew 16.9% YoY to ₹4,019 million. The company also reported an exceptional item of ₹257 million for 9MFY26 related to incremental liability for Gratuity and Compensated Absences under the new Labour Code.

The management expressed confidence in sustaining margin expansion and projected high single-digit revenue growth for the full year FY26, driven by the strength of its core business and increased contributions from new product launches. The CDMO business demonstrated a strong turnaround, with revenues growing 85.3% YoY and 100% QoQ. Non-GPL (Generic Pharmaceutical) business continued its robust growth, up 16.1% YoY for 9MFY26, across key markets like Europe, Japan, LATAM, ROW, and India.

Financially, the company generated a strong free cash flow of ₹2,207 million in 9MFY26, bolstering its cash and cash equivalents to ₹7,330 million as of December 31, 2025. Return indicators such as Return on Invested Capital Employed (ROICE) were tracking around 31% for 9MFY26.

Looking ahead, Alivus Life Sciences outlined its strategy focusing on building a sustainable, long-term business through high-quality offerings, innovation, and scalable operations. Growth levers include expanding the Gx API business, developing new platforms like CDMO ramp-up, complex API platforms, iron compounds, and Oncology & HP API. Significant capacity expansions are underway at Solapur (Greenfield), Dahej, and Ankleshwar. The company also acquired land in Taloja for a new state-of-the-art R&D center. Risks are outlined in the disclaimer, including general economic and regulatory factors.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced its financial results for the third quarter and nine months ended December 31, 2025 (Q3FY26), reporting its strongest performance to date.

Quarterly/Annual Results: For Q3FY26, the company achieved record revenues from operations of Rs 6,729 Mn, marking a significant increase of 14.4% quarter-on-quarter (QoQ) and 4.8% year-on-year (YoY). For the nine months ended December 31, 2025 (9MFY26), revenue stood at Rs 18,627 Mn, showing a YoY growth of 7.2%. EBITDA for Q3FY26 was Rs 2,452 Mn, up 26.5% QoQ and 22.1% YoY. EBITDA margins reached an all-time high of 36.4%, expanding by 340 basis points (bps) QoQ and 510 bps YoY, driven by a favourable product mix, recovery in the CDMO business, new product contributions, and operational efficiencies. For 9MFY26, EBITDA was Rs 6,204 Mn, up 22.0% YoY, with EBITDA margins at 33.3% (up 400 bps YoY). Profit After Tax (PAT) for Q3FY26 was Rs 1,503 Mn (up 15.5% QoQ, 9.7% YoY), with PAT margins at 22.3% (up 100 bps YoY). For 9MFY26, PAT was Rs 4,019 Mn (up 16.9% YoY), and PAT margins were 21.6% (up 180 bps YoY).

Guidance & Concall Commentary: Dr. Yasir Rawjee, MD & CEO, highlighted the strong recovery in the CDMO business and robust 16% YoY growth in the Non-GPL business during 9MFY26 across key markets. The company anticipates sustaining this momentum to deliver high single-digit revenue growth for the full year FY26 and is confident in maintaining margin expansion. CFO Tushar Mistry reiterated the focus on disciplined growth, achieving record EBITDA margins, and maintaining a strong net debt-free financial position.

Financials: The company generated a free cash flow of Rs 2,207 Mn during 9MFY26. As of December 31, 2025, Alivus Life Sciences maintained a strong liquidity position with Rs 7,330 Mn in cash and cash equivalents, including short-term investments, confirming its status as a net debt-free entity.

Key Events: Significant operational developments include ongoing construction for 465 KL capacity at Solapur (Phase 1 and 1.1). Furthermore, the company has acquired land in Taloja (Navi Mumbai) to establish a new state-of-the-art R&D centre, which will focus on complex chemistry, oncology research, flow chemistry, particle engineering, and green chemistry to enhance its product pipeline. Cumulative filings for Drug Master Files (DMF) / Certificates of Suitability (CEP) reached 595 as of December 31, 2025. The HP API portfolio includes 27 products in the active grid.

Outlook: Management expressed confidence in future performance, driven by the strength of its core business, continued contributions from new product launches, and the strategic investments in R&D and capacity expansion. The company aims to build a sustainable, long-term business through high-quality offerings and innovation.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced its unaudited financial results for the third quarter and the nine months ended December 31, 2025. The company reported its financial performance for the period.

Quarterly and Nine-Month Results:
For the third quarter ended December 31, 2025, Revenue from Operations stood at ₹672.89 Crore, showing a year-on-year (YoY) increase of 4.84% from ₹641.84 Crore in Q3 FY25, and a quarter-on-quarter (QoQ) growth of 14.44% from ₹587.98 Crore in Q2 FY26. The Profit After Tax (PAT) for Q3 FY26 was ₹150.26 Crore, up 9.71% YoY from ₹136.96 Crore in Q3 FY25, and a significant 15.56% increase QoQ from ₹130.03 Crore in Q2 FY26. The Earnings Per Share (EPS) for the quarter was ₹12.25 (basic), compared to ₹11.18 in Q3 FY25.

For the nine months ended December 31, 2025, Revenue from Operations was reported at ₹1900.35 Crore, an increase of 7.86% YoY from ₹1761.82 Crore in 9M FY25. The PAT for the nine-month period grew by 16.90% YoY to ₹401.82 Crore, from ₹343.76 Crore in 9M FY25. Basic EPS for 9M FY26 was ₹32.76, up from ₹28.06 in 9M FY25.

Financials and Exceptional Items:
Total Income for Q3 FY26 was ₹686.82 Crore. Total Expenses amounted to ₹462.77 Crore. Profit Before Exceptional Items stood at ₹224.05 Crore. The company reported an exceptional item of ₹25.66 Crore, identified as the 'Statutory impact of new labour codes'. This impact, comprising gratuity and compensated absences due to revised wage definitions under the new Labour Codes effective November 21, 2025, was recognised as past service cost. Consequently, Profit Before Tax (PBT) for Q3 FY26 was ₹198.39 Crore, and the Total Tax Expense was ₹48.13 Crore, leading to the PAT of ₹150.26 Crore. Balance sheet and cash flow details were not provided in this excerpt. The company operates in a single reporting segment: Active Pharmaceutical Ingredient (API).

Guidance, Outlook, and Events:
No specific forward-looking guidance or outlook was provided by the management in this announcement. The results were subjected to a limited review by the statutory auditor, Walker Chandiok & Co. LLP, who expressed an unmodified conclusion. The company also noted that as of December 31, 2025, 600,631 employee stock options were outstanding.

Alivus Life Sciences: Q3 FY26 Financial Results Analysis

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced its unaudited financial results for the third quarter and nine months ended December 31, 2025.

Quarterly & Nine-Month Performance

Third Quarter Ended December 31, 2025 (vs. Q3 FY25):

• Revenue from operations grew by 4.84% year-over-year (YoY) to ₹6,728.89 million.
• Profit After Tax (PAT) increased by 9.72% YoY to ₹1,502.61 million.
• Basic Earnings Per Share (EPS) rose to ₹12.25 from ₹11.18 YoY.
• Profit Before Tax (PBT) stood at ₹1,983.92 million, a 7.15% YoY increase, impacted by an exceptional item.

Nine Months Ended December 31, 2025 (vs. 9M FY25):

• Revenue from operations saw a slight decline of 1.39% YoY to ₹17,373.39 million.
• Profit After Tax (PAT) demonstrated robust growth of 16.90% YoY to ₹4,018.22 million.
• Basic Earnings Per Share (EPS) increased to ₹32.76 from ₹28.06 YoY.
• Profit Before Tax (PBT) increased by 15.71% YoY to ₹5,355.10 million.

Financial Deep Dive & Key Events

Exceptional Item:
The company recognized an exceptional item of ₹256.57 million in the current period (Q3 FY26 and 9M FY26) representing the statutory impact of new labor codes. This primarily comprises incremental costs for gratuity and compensated absences, accounted for as past service cost. Excluding this item, Profit Before Exceptional Items showed stronger growth of 21.01% YoY for Q3 and 21.25% YoY for 9M FY26.

Segmental Performance:
Alivus Life Sciences operates in a single reporting segment: Active Pharmaceutical Ingredient (API).

Auditor's Review:
The financial results for the period were subjected to a limited review by the statutory auditor, Walker Chandiok & Co LLP, who expressed an unmodified conclusion.

Outlook

No specific forward-looking guidance or outlook was provided in the disclosed financial results. The company also did not report any major corporate actions, order wins, or expansions.

Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, has officially announced the allotment of equity shares under its 'Employee Stock Option Scheme, 2021'. The company's Nomination and Remuneration Committee convened a meeting on January 21, 2026, and approved the issuance of 55,000 equity shares. These shares, each with a face value of Rs. 2, were allotted to an eligible employee who had exercised their vested stock options. This corporate action has resulted in an increase in the company's total paid-up share capital. Prior to the allotment, the company had 12,26,81,348 equity shares of Rs. 2 each, aggregating to Rs. 24,53,62,696. Post allotment, the number of equity shares has risen to 12,27,36,348, aggregating to Rs. 24,54,72,696. This represents a marginal expansion of the equity base. The announcement was made to the stock exchanges, BSE Ltd. and National Stock Exchange of India Ltd., for record purposes. The news does not contain any information regarding quarterly or annual financial results, management guidance, future outlook, or significant operational performance metrics.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced the schedule for its upcoming earnings call to discuss its financial performance for the third quarter and the nine months ended September 30, 2025. The call is set for Thursday, January 22, 2026, from 6:00 PM to 7:00 PM IST. Participants can access the call through provided universal dial-in numbers and international toll-free/toll numbers, with an option for online pre-registration. This announcement precedes the official release of Q3 FY26 results, serving as a key event for management to communicate financial outcomes, address investor queries, and provide insights into the company's strategic direction and future outlook. In line with SEBI regulations, the company has implemented a trading window closure for designated persons from December 31, 2025, to January 24, 2026.

Alivus Life Sciences Limited announced on January 14, 2026, that a meeting of its Board of Directors is scheduled for Thursday, January 22, 2026. The primary purpose of this meeting is to consider and approve the company's unaudited financial results for the third quarter and the nine-month period ended December 31, 2025. This disclosure is made pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, in accordance with the 'Code of Conduct for Prevention of Insider Trading' and SEBI (Prohibition of Insider Trading) Regulations, 2015, the company has informed its designated persons about the closure of the trading window. The trading window will remain shut from December 31, 2025, to January 24, 2026, inclusive, for the purpose of the approval of these financial results. The announcement serves as a formal notification to stakeholders regarding these upcoming corporate actions.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences) has formally notified the stock exchanges regarding an upcoming Board Meeting. The meeting is scheduled to take place on Thursday, January 22, 2026. The primary agenda for this meeting is to consider and approve the company's unaudited financial results for the quarter and the first nine months of the financial year ending December 31, 2025. In accordance with SEBI regulations, specifically the 'Code of Conduct for Prevention of Insider Trading' and SEBI (Prohibition of Insider Trading) Regulations, 2015, the company has also declared a closure of the trading window for its 'designated persons'. This trading window will remain closed from December 31, 2025, up to January 24, 2026, inclusive. This measure is standard practice to ensure fair disclosure and prevent potential insider trading activities related to the upcoming financial results.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has formally disclosed its schedule for upcoming investor and analyst meetings throughout December 2025. These engagements include one-on-one sessions, such as the in-person meeting with Kosh Wealth Management in Mumbai on December 30, 2025, and others scheduled until December 18th, 2025 with various investors and PMS providers. The company noted that the schedule and mode of meetings are subject to change. In parallel, Alivus Life Sciences has announced a change in its corporate office address, relocating to Technopolis Knowledge Park, Andheri East, Mumbai.

These disclosures follow a period of robust financial performance, notably the strong Q2 FY2025-26 results which saw revenue climb 16.0% YoY to ₹5,880 million and PAT surge 36.5% YoY to ₹1,301 million, with EBITDA margins expanding to 33.0%. For the full fiscal year 2026, management guidance projects high single-digit revenue growth and stable EBITDA margins around 30%. The company continues to maintain a net debt-free status, bolstered by substantial cash reserves of ₹6,526 million. Creditworthiness has been reinforced with an 'IND AA' rating upgrade from India Ratings. Operational highlights include successful US FDA inspections and plans for the Solapur plant to commence operations in Q4 FY26. While the company is addressing regulatory penalties from GPCB, GST, and Customs, it has stated that these have no material impact on its operations or financials.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced a schedule of investor and analyst meetings to be held virtually and in-person from December 23 to December 29, 2025. These engagements are with Omega Portfolio, Mount Intra Finance, Choice India, and Centrum PMS. This announcement follows the company's strong performance reported for Q2 FY2025-26.

Quarterly/Annual Results:
For Q2 FY26, Alivus Life Sciences reported revenue from operations of ₹5,880 million, a 16.0% year-on-year increase. Profit After Tax (PAT) surged by 36.5% YoY to ₹1,301 million. EBITDA rose 35.7% YoY to ₹1,939 million, with EBITDA margins expanding by 480 basis points YoY to 33.0%. For the half-year ended September 30, 2025 (H1 FY26), revenue grew 8.6% YoY to ₹11,898 million. The company generated ₹1,477 million in free cash flow during H1 FY26 and maintained cash reserves of ₹6,526 million. The company also noted successful US FDA inspections at its Dahej and Ankleshwar facilities and that its Solapur plant is slated to commence operations in Q4 FY26.

Guidance & Concall Commentary:
Management guides for high single-digit revenue growth for FY26, with stronger momentum expected in H2 FY26. EBITDA margins are expected to remain robust, around the 28-30% range. The company aims to grow its Contract Development and Manufacturing Organization (CDMO) business to 12-15% of revenue within 4-5 years.

Financials:
The company maintained a net debt-free status with ₹6,526 million in cash reserves as of the end of Q2 FY26. India Ratings upgraded Alivus Life Sciences' bank loan facilities to 'IND AA' with a Stable Outlook, citing strong FY25 operational performance, healthy revenue visibility, robust EBITDA margins, and a strengthened net cash position. Revenue grew 4.5% YoY to ₹23,869 million and EBITDA rose 1.2% to ₹6,826 million for FY25, with improved free cash flow.

Key Events:
The company has faced several regulatory notices: a penalty of approximately ₹3.21 crore from Customs for alleged mis-classification of goods, a GST demand of ₹1.28 crore plus penalty for FY18-19 and FY23-24, and an environmental damage compensation of ₹50 lakhs from GPCB following a fire incident. In each case, the company states there is no material financial impact and is evaluating its options, including appeals.

Alivus Life Sciences also completed its 14th Annual General Meeting (AGM) on September 8, 2025, approving financial statements and declaring a final dividend of ₹5 per equity share. A corporate action involving the allotment of 52,200 equity shares to employees under its ESOP scheme occurred in August 2025. The company also notified a change in its corporate office address.

Outlook:
The outlook remains positive, driven by expected high single-digit revenue growth, sustained EBITDA margins around 30%, the ramp-up of the CDMO business, and strategic capacity expansions including the Solapur facility. The company continues to focus on expanding its non-GPL business and improving visibility for its GPL segment.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences, is actively engaged in investor relations, with a series of investor and analyst meetings scheduled throughout December 2025, including a virtual meeting with Choice India on December 18, 2025. This communication follows the company's strong financial performance for Q2 FY2025-26.

Quarterly/Annual Results: The company reported robust Q2 FY26 results, with revenue from operations growing by 16.0% year-on-year (YoY) to ₹5,880 million. Profit After Tax (PAT) surged by 36.5% YoY to ₹1,301 million. EBITDA increased by 35.7% YoY to ₹1,939 million, and EBITDA margins expanded significantly by 480 basis points (bps) YoY to 33.0%. For the half-year ended September 30, 2025 (H1 FY26), revenue rose by 8.6% YoY to ₹11,898 million.

Guidance & Concall Commentary: For the full fiscal year 2026 (FY26), management has guided for high single-digit revenue growth. Stronger momentum is anticipated in the second half of FY26 (H2 FY26), driven by continued strength in the non-GPL segment, improved visibility for GPL, and ramp-up in the CDMO business. The company aims to grow its CDMO business to 12-15% of revenue within 4-5 years and expects EBITDA margins to remain stable around 30%.

Financials: Alivus Life Sciences continues to maintain a net debt-free status, ending Q2 FY26 with ₹6,526 million in cash reserves. India Ratings has upgraded the company's bank loan facilities to 'IND AA' with a Stable Outlook, reflecting its strong operational performance and credit metrics. Capital expenditure is ongoing for the Solapur facility's Phase 1, which is expected to commence operations in Q4 FY26.

Key Events: The company announced successful US FDA inspections at its Dahej and Ankleshwar facilities. It has also addressed several regulatory matters, including penalties from the Office of Commissioner of Customs (approximately ₹3.21 crore), the Goods and Service Tax Department (₹1.28 crore tax, ₹1.29 crore penalty), and an interim order from the Gujarat Pollution Control Board (GPCB) imposing an environmental damage compensation of ₹50 lakhs following a fire incident at its Ankleshwar Plant on September 30, 2025. Alivus Life Sciences has stated that these regulatory actions have no material impact on its financial or operational activities and is evaluating appeal options. An allotment of 52,200 equity shares under the Employee Stock Option Scheme was also completed. The 14th Annual General Meeting (AGM) on September 8, 2025, approved the FY25 financial statements and a final dividend of ₹5 per equity share.

The current report is an official disclosure from Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) regarding its upcoming investor and analyst engagement schedule. The company has announced that representatives will participate in a series of one-on-one meetings between December 16th and December 18th, 2025. These meetings are a part of the company's ongoing investor relations efforts.

Specifically, in-person meetings are scheduled in Mumbai with Unique PMS on December 16th, Yes Securities on December 16th, JM Financial on December 17th, and SIMPL on December 18th. Additionally, a virtual one-on-one meeting with Systematix is scheduled for December 18th.

This disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company has also noted that the schedule and the mode of these meetings may be subject to change due to exigencies on the part of the investor/analyst or the company. No financial results, performance updates, or forward-looking guidance are included in this specific announcement.

This SSL Research morning update for December 5, 2025, provides a snapshot of market expectations and key actionable news for investors. The market is anticipated to open flat ahead of the RBI MPC policy outcome, with attention on rate-sensitive sectors like Auto, Banks, NBFCs, and Realty. Global markets showed mixed performance, with Wall Street ending mixed and Asian indices largely trading in the red.

Significant corporate actions highlighted include British American Tobacco's intention to offload shares worth nearly Rs 3,000 crore in ITC Hotels, a move deemed negative in the short to medium term. Positively, Shriram Pistons & Rings Ltd is set to acquire 100% stake in Antolin Lighting India and Grupo Antolin India for an enterprise value of approximately Rs 1,670 crore, expanding its presence in automotive interior and lighting solutions.

Other key developments include positive medium to long-term prospects for Seamec and Lloyds Engineering due to new pacts in offshore vessel charter and radar technology development, respectively. RailTel Corp and Zen Tech have received work orders and supply orders worth Rs 63.9 crore and Rs 120 crore, respectively, from government entities, while Diamond Power secured a Rs 748 crore order from Adani Green for cable supply. Deepak Nitrite's arm commenced operations at a new Nitric acid plant, a neutral short-term development. Excelsoft Tech's partnership with AQA for AI R&D is viewed positively for the medium to long term.

The report also details the subscription status of ongoing IPOs for Meesho, Aequs, and Vidya Wires, with Aequs showing strong subscription figures. Promoters made significant purchases in TGV Sraac, Greenply Industries, Aarti Pharmalabs, Usha Martin, and Maharashtra Seamless. Numerous stocks experienced price band revisions from 10% to 20% or 5% to 10%. Important corporate actions like ex-demerger dates, ex-rights issues, and shares exiting anchor lock-in periods are listed. Fund flow data for December 4th shows net inflows from DIIs (Rs +3,661.1 crore) and net outflows from FIIs (Rs -1,994.2 crore).

This report details numerous bulk deals executed on the BSE and NSE on December 4th, 2025. It lists specific transactions, including buyer/seller names, security codes, quantities, and prices for various companies such as ALIVUS (BSE: 543322), ALSTONE (BSE: 539277), AMITINT (BSE: 531300), ATISHAY (BSE: 538713), BGJL (BSE: 540545), CAPILLARY (BSE: 544614), Delta Corp Limited (NSE), Global Surfaces Limited (NSE), Greenlam Industries Ltd. (NSE), Jyoti Global Plast Ltd (NSE), Nectar Lifesciences Limit (NSE), Paramount Dye Tec Limited (NSE), Pelatro Limited (NSE), Pramara Promotions Ltd (NSE), and Softtech Engineers Ltd (NSE), among many others. The report also includes comprehensive disclosures and disclaimers from Nirmal Bang Securities Private Limited (NBSPL), a registered Research Analyst and Stock Broker. These disclosures outline NBSPL's regulatory standing, independence from subject companies, conflict of interest policies, and standard legal disclaimers regarding the use of their research reports. No specific financial performance metrics, quarterly/annual results, management guidance, or forward-looking outlook for any of the mentioned companies are provided in this document.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences, has announced scheduled investor and analyst meetings. Notably, the company will conduct an in-person, one-on-one meeting with Quantum AMC in Mumbai on December 09, 2025. This disclosure adheres to SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, and is part of the company's ongoing investor relations program. The meetings are designed to foster dialogue on the company's business performance, strategic initiatives, and future growth prospects. This engagement follows the company's strong Q2 FY26 financial performance, which reported a 16.0% year-on-year revenue growth to ₹5,880 Mn and a significant 36.5% year-on-year PAT increase to ₹1,301 Mn, with EBITDA margins expanding by 480 basis points to 33.0%. Management's guidance for FY26 projects high single-digit revenue growth and stable EBITDA margins around 30%. Alivus Life Sciences maintains a net debt-free position with substantial cash reserves and benefits from an 'IND AA' credit rating. While recent disclosures included regulatory notices from GST and Customs and a GPCB penalty, the company has stated these have no material impact on its operations or financials. The schedule and mode of meetings are subject to change due to exigencies.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences) has formally notified stock exchanges about upcoming investor and analyst meetings. Pursuant to SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the company's representatives will attend a virtual one-on-one meeting with Kosh Wealth Management on December 4, 2025. This will be followed by an in-person one-on-one meeting with Karma Capital in Mumbai on December 5, 2025. These engagements are routine disclosures aimed at facilitating discussions with institutional investors and analysts regarding the company's operations, performance, and strategic initiatives. The company has noted that the schedule and mode of these meetings may be subject to change due to unforeseen circumstances.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences) has scheduled investor and analyst meetings for December 2nd and 3rd, 2025. The company's representatives will hold in-person, one-on-one meetings in Mumbai with Axis Securities PMS on December 2nd and with Old Bridge Capital on December 3rd. These engagements are standard disclosures under SEBI regulations.

This news follows the company's strong Q2 FY26 financial results, where revenue from operations grew by 16.0% year-on-year to ₹5,880 Mn, and Profit After Tax (PAT) surged by 36.5% YoY to ₹1,301 Mn. EBITDA increased by 35.7% YoY to ₹1,939 Mn, with EBITDA margins expanding by 480 basis points to 33.0%, driven by a 39.7% YoY growth in the non-GPL segment. For the half-year ended September 30, 2025 (H1 FY26), revenue rose 8.6% YoY to ₹11,898 Mn.

Management has guided for high single-digit revenue growth in FY26, expecting stronger momentum in H2 FY26, and anticipates maintaining healthy EBITDA margins around 30%. The company maintains a net debt-free status with cash reserves of ₹6,526 Mn as of Q2 FY26.

Recent operational highlights include successful US FDA inspections at its Dahej and Ankleshwar facilities, and the Solapur plant is expected to commence operations in Q4 FY26. The company aims to grow its CDMO business to 12-15% of revenue within 4-5 years.

Alivus Life Sciences also reported several regulatory and penalty-related events. These include an interim order from the Gujarat Pollution Control Board (GPCB) for environmental damage compensation following a September 30, 2025 incident, an order from the Goods and Service Tax Department for tax liabilities and penalties, and penalties from the Office of Commissioner of Customs. The company has stated these have no material impact and is evaluating appeals where applicable. Additionally, the company officially notified a change in its corporate office address.

The company's 14th Annual General Meeting was held on September 8, 2025, where shareholders approved the audited financial statements for FY 2024-25 and a final dividend of ₹5 per equity share.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences) has announced scheduled investor and analyst meetings for November 2025. The company will hold a one-on-one in-person meeting with Quantum AMC in Mumbai on November 19, 2025, and a virtual one-on-one meeting with Axis Securities PMS on November 24, 2025. These engagements are part of the company's proactive investor relations strategy, aiming to foster dialogue on its performance and outlook. This announcement follows Alivus Life Sciences' strong Q2 FY26 financial results, which saw revenue increase by 16.0% year-on-year to ₹5,880 Mn and Profit After Tax (PAT) surge by 36.5% year-on-year to ₹1,301 Mn. EBITDA margins expanded significantly to 33.0%, driven by strong performance in the non-GPL segment. For the full fiscal year 2026, management guides for high single-digit revenue growth and expects sustained healthy EBITDA margins around 30%, with stronger momentum anticipated in the second half of the year. The company continues to maintain a robust financial position, being net debt-free with substantial cash reserves, and recently saw its bank loan facilities upgraded to 'IND AA' by India Ratings. Key operational developments include the progression of capacity expansions, with the Solapur facility slated for commencement in Q4 FY26, and strategic efforts to grow the CDMO business. Recent regulatory matters, including GPCB and GST notices, are being managed, with the company asserting no material financial or operational impact and exploring appeal options, while also reporting successful US FDA inspections.

Alivus Life Sciences Limited announced its Q2 FY26 financial results, reporting a significant 16.0% year-on-year increase in revenue to ₹5,880 million and a 35.7% YoY jump in EBITDA to ₹1,939 million. EBITDA margins expanded by 480 basis points to 33.0%, driven by a 57.7% gross margin and growth in the non-GPL segment. Profit After Tax (PAT) grew by 36.5% YoY to ₹1,301 million. For the first half of FY26, revenue increased by 8.6% YoY to ₹11,898 million, with EBITDA up 21.9% YoY. The company maintained its net debt-free status, ending the quarter with ₹6,526 million in cash reserves. Management reaffirmed its guidance for high single-digit revenue growth for FY26, anticipating stronger performance in the second half due to continued non-GPL strength, recovery in the GPL business, and ramp-up of CDMO projects. They expressed confidence in sustaining EBITDA margins around 30%. Growth is being fueled by successful new product launches, strong regional performance, and strategic capacity expansions at Solapur, Ankleshwar, and Dahej. The company also highlighted its 'API plus' model, offering value-added services to customers. Regulatory updates include successful US FDA inspections at Ankleshwar and Dahej facilities, while an interim order from GPCB imposed a ₹50 lakh penalty for an environmental incident, with no material impact stated.

Alivus Life Sciences Limited, previously known as Glenmark Life Sciences Limited, has fulfilled its disclosure obligations by making the audio recording of its Q2 FY2026 earnings call available to the public. The call, held on November 07, 2025, is now accessible on the company's official website via a provided link. This compliance with Regulation 30 and 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, allows investors to review the detailed discussions by the management concerning the company's financial results, operational performance, strategic initiatives, and future outlook. The company has requested that this filing be taken on record by the stock exchanges.

Alivus Life Sciences posted strong Q2 FY26 results, marked by a 16.0% YoY revenue growth to ₹5,880 Mn and a significant 35.7% YoY increase in EBITDA to ₹1,939 Mn. This performance was primarily fueled by the non-GPL business segment, which saw a robust 39.7% YoY expansion. The company also reported a substantial improvement in its EBITDA margin, up 480 bps YoY to 33.0%, and PAT grew 36.5% YoY to ₹1,301 Mn. Management provided a confident outlook for the second half of FY26, expecting continued strength from the non-GPL segment, improved visibility on the GPL business, and ramp-up in CDMO projects.

For Q2 FY26, Alivus Life Sciences reported revenue from operations of ₹5,880 Mn, a 16.0% YoY increase and a 2.3% QoQ decrease. Gross Profit stood at ₹3,391 Mn, up 20.4% YoY, with Gross Margins improving to 57.7% (+210 bps YoY). EBITDA reached ₹1,939 Mn, a 35.7% YoY surge, and EBITDA Margin expanded by 480 bps YoY to 33.0%. PAT was ₹1,301 Mn, up 36.5% YoY, with Net Margins at 22.1% (+330 bps YoY). For H1 FY26, revenue grew 8.6% YoY to ₹11,898 Mn, EBITDA increased 21.9% YoY to ₹3,752 Mn (31.5% margin), and PAT grew 21.7% YoY to ₹2,516 Mn (21.1% margin).

Management expressed strong confidence in delivering a better performance in H2 FY26, underpinned by the sustained robustness of the non-GPL business and enhanced visibility for the GPL segment. The ongoing ramp-up of CDMO projects also contributes to this positive outlook. The company is committed to maintaining its EBITDA margins around the 30% level, even without PLI benefits, driven by a healthy pipeline of new product launches and ongoing operational efficiencies.

Key income statement drivers showed robust YoY growth in revenue, gross profit, EBITDA, and PAT, coupled with significant margin expansion. The company maintained a strong balance sheet, with cash and cash equivalents (including short-term investments) totalling ₹6,526 Mn as of September 30, 2025, bolstered by a free cash flow generation of ₹1,477 Mn in Q2 FY26. The ROICE was approximately 29% for H1 FY26, indicating efficient capital deployment.

Segmental analysis revealed a 15.3% YoY growth in Generic API revenue and 15.8% YoY growth in CDMO business, with the latter projected for strong H2 FY26 performance. The GPL business experienced a 23.9% YoY de-growth due to inventory rationalization but is expected to improve. Geographically, regulated markets constituted 81% of Q2 FY26 revenue, driven by LATAM, Japan, and Europe. The company is actively progressing with multiple capacity expansion projects, including a Greenfield development at Solapur and Brownfield expansions at Ankleshwar and Dahej, to support future growth.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced strong financial results for the second quarter and half year ended September 30, 2025.

Quarterly & Half Yearly Performance:

• Q2FY26: Revenue from operations stood at ₹5,880 Mn, marking a significant YoY growth of 16.0%. EBITDA was ₹1,939 Mn (+35.7% YoY) with EBITDA margins at 33.0%, an improvement of 480 basis points YoY. Profit After Tax (PAT) was ₹1,301 Mn (+36.5% YoY), with PAT margins at 22.1% (+330 bps YoY).
• H1FY26: Revenue from operations reached ₹11,898 Mn, showing YoY growth of 8.6%. EBITDA was ₹3,752 Mn (+21.9% YoY) with margins at 31.5% (+340 bps YoY). PAT was ₹2,516 Mn (+21.7% YoY) with margins at 21.1% (+220 bps YoY).

Management Commentary & Outlook:
Dr. Yasir Rawjee, MD & CEO, attributed the Q2FY26 performance to strong momentum in the non-GPL business, which grew by an impressive 39.7% YoY, driven by healthy demand across key geographies. He expressed confidence in delivering a stronger performance in the second half of FY26, supported by continued non-GPL robustness, better visibility on GPL business, and the ramp-up of CDMO projects. The company remains confident in maintaining margins around 30%, even without PLI benefits, supported by a robust pipeline of new launches and operational efficiencies.

Tushar Mistry, CFO, noted that Q2FY26 gross margins (57.7%) and EBITDA margins (33.0%) were at the upper end of guided ranges (above 55% and 30%), supported by a favourable product mix, new launches, and cost efficiency. The company highlighted its debt-free status and sufficient cash reserves.

Financial Deep Dive:

• Cash Flow: The company generated a strong free cash flow of ₹1,477 Mn in H1FY26. In Q2FY26, it generated ₹148 crores (₹1,480 Mn) from operations.
• Liquidity: Cash and Cash Equivalents (including short-term investments) stood at ₹6,526 Mn as of September 30, 2025. The company maintains a healthy, debt-free balance sheet.

Key Developments:

• Regulatory Filings: Cumulative DMF/CEP filings reached 586 as of September 30, 2025.
• API Portfolio: The HP API portfolio has 26 APIs in the active grid, with detailed development stages noted.
• Capex: Phase 1 construction for 200 KL capacity is in progress at Solapur.

The company supplies APIs in chronic therapeutic areas and is expanding its CDMO services.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced its unaudited financial results for the Second Quarter (Q2) and Half Year (H1) ended September 30, 2025. The company reported strong year-over-year (YoY) growth across key financial metrics.

Quarterly Results (Q2 FY26 vs Q2 FY25):

• Revenue from Operations: ₹5,879.80 million, up 15.98% YoY (vs ₹5,068.79 million). QoQ growth was 103.50% (vs ₹2,889.61 million in Q1 FY26).
• Profit Before Tax (PBT): ₹1,741.37 million, up 36.62% YoY (vs ₹1,274.56 million). QoQ growth was 6.84% (vs ₹1,629.81 million in Q1 FY26).
• Profit for the Period (PAT): ₹1,300.26 million, up 36.42% YoY (vs ₹953.16 million). QoQ growth was 6.99% (vs ₹1,215.35 million in Q1 FY26).
• PBT Margin: Improved to 28.89% in Q2 FY26 from 24.73% in Q2 FY25.
• Basic EPS: ₹10.60, up 6.96% YoY (vs ₹9.91 in Q2 FY25).

Half-Yearly Results (H1 FY26 vs H1 FY25):

• Revenue from Operations: ₹11,898.26 million, up 8.61% YoY (vs ₹10,954.95 million).
• Profit Before Tax (PBT): ₹3,371.18 million, up 21.38% YoY (vs ₹2,776.94 million).
• Profit for the Period (PAT): ₹2,515.61 million, up 21.64% YoY (vs ₹2,067.99 million).
• PBT Margin: Improved to 27.78% in H1 FY26 from 25.03% in H1 FY25.
• Basic EPS: ₹20.51, up 21.50% YoY (vs ₹16.88 in H1 FY25).

The company operates in a single segment: Active Pharmaceutical Ingredient (API). The balance sheet as of September 30, 2025, shows Total Assets of ₹36,383.43 million. The company maintains a healthy net cash position, estimated at over ₹6.5 billion, with a very low Debt-to-Equity ratio of approximately 0.02. The current ratio stood at a robust 5.06. Cash Flow from Operations for H1 FY25 was ₹2,607.29 million, and after accounting for CapEx of ₹1,129.85 million, the company generated positive Free Cash Flow of approximately ₹1,477 million. Dividend paid in H1 FY25 amounted to ₹613.42 million. No specific guidance, outlook, major orders, or new product launches were detailed in this results announcement.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, has formally announced its upcoming earnings call to present the financial performance for the second quarter of the fiscal year 2025-26 (Q2 FY2025-26). The call is scheduled for Friday, November 7, 2025, and will run from 8:30 a.m. to 9:30 a.m. Indian Standard Time (IST).

This announcement serves as an official invitation to investors, analysts, and other interested parties. While the actual financial results, including revenue, profit, margins, and EPS, along with management guidance and detailed financial deep dives, are not part of this initial announcement, they are expected to be the primary focus during the earnings call itself.

The company has provided comprehensive participation details. This includes universal dial-in numbers for India (+91 22 6280 1564, +91 22 7115 8394) and a wide array of international toll-free and toll numbers covering regions such as Australia, Canada, China, Hong Kong, Italy, Japan, Singapore, South Korea, the UK, and the USA. A link for participants to pre-register online is also available.

The earnings call is anticipated to be a critical forum for management to articulate the company's strategic direction, discuss key growth drivers, address any potential risks, and provide an outlook for the upcoming periods. Following the presentation of Q2 results, a question-and-answer session will allow stakeholders to seek clarification directly from the company's leadership. Contact details for EY representatives, Diwakar Pingle and Runjhun Jain, are provided for any queries related to the call logistics.

Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, has issued a formal communication to the BSE and NSE, announcing a forthcoming meeting of its Board of Directors. Scheduled for Thursday, November 06, 2025, the board's primary agenda item will be the consideration and approval of the company's unaudited financial results for the second quarter and the first half of the financial year ended September 30, 2025. This announcement is made pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.

In conjunction with this financial reporting event, the company has also implemented a closure of the trading window for its 'designated persons'. This restriction, in effect from September 30, 2025, to November 08, 2025, inclusive, is in compliance with SEBI's Prohibition of Insider Trading Regulations, 2015, and the company's internal code of conduct. The purpose is to prevent any potential misuse of unpublished price-sensitive information ahead of the official results disclosure.

As this is an advance notification of a board meeting, no specific financial performance figures, such as revenue, EBITDA, Profit After Tax (PAT), Earnings Per Share (EPS), or margin details for the quarter or half-year ended September 30, 2025, are provided in this filing. Similarly, there is no management guidance, outlook commentary, or details on significant events like orders, expansions, or regulatory updates. Investors and market participants will have to await the official results announcement following the board meeting for a comprehensive understanding of the company's financial health and performance trends.

Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, has formally announced through stock exchange filings (BSE and NSE) that its Board of Directors will convene for a meeting on Thursday, November 06, 2025. The primary agenda item for this board meeting is the consideration and approval of the company's un-audited financial results for the second quarter and the first half of the fiscal year ending September 30, 2025.

In accordance with SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, and the company's internal 'Code of Conduct for Prevention of Insider Trading' based on SEBI (Prohibition of Insider Trading) Regulations, 2015, Alivus Life Sciences has also implemented a closure of the trading window. This window will remain shut for all designated persons of the company from September 30, 2025, up to and including November 08, 2025. The purpose of this closure is to prevent any potential misuse of unpublished price-sensitive information concerning the financial results announcement. Investors await the financial performance figures for the reported periods. No specific guidance or detailed financial projections have been provided at this stage, only the announcement of the board meeting date for results approval.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has disclosed receiving a notice and order from the Gujarat Pollution Control Board (GPCB) on October 18, 2025, around 11:00 am. The GPCB has imposed an interim environmental damage compensation of Rs. 50 lakhs. The company has been directed to deposit Rs. 29 lakhs immediately. Furthermore, a bank guarantee of Rs. 10,00,000/- is required for compliance assurance at the time of revocation of the order. This action by the GPCB is in response to a flash fire incident that occurred at Unit No. 6 of Alivus Life Sciences' Ankleshwar Plant on September 30, 2025. The company, in its disclosure, stated that there is no material impact on its financial standing, operations, or other activities resulting from the incident or the imposition of this penalty. Alivus Life Sciences also noted that the order is currently appealable and the company will assess its right to appeal. The disclosure was made pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has been served an order by the Goods and Service Tax Department, specifically from the Assistant Commissioner of Central GST, Ankleshwar. This order, dated 01st October, 2025, was received on the same day around 6:00 PM. It pertains to alleged violations or contraventions under Section 74(1) and 122(1) of the Central Goods & Service Tax Act, 2017, for the Financial Years 2018-19 and 2023-24. The order entails a demand for ₹1,28,07,007 towards tax liability. In addition, a penalty amounting to ₹1,29,43,759 has been imposed, along with applicable interest. Despite the quantum of the demand and penalty, Alivus Life Sciences has stated that there is no material impact on its financial, operational, or other activities as a result of this intimation of tax payable. The company has also noted that the order is currently appealable, and it will undertake an assessment to determine whether to exercise its right to appeal. This disclosure falls under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

India Ratings and Research has upgraded Alivus Life Sciences Limited’s bank loan facilities to ‘IND AA’ from ‘IND AA-’ with a Stable Outlook, affirming the short-term rating at ‘IND A1+’. The upgrade is driven by the company's strong operational performance in FY25, characterized by healthy revenue visibility, robust EBITDA margins (28.6%), and a strengthened net cash position.

In FY25, Alivus Life Sciences reported revenue of INR 23,869 million, a 4.5% year-on-year increase, accompanied by EBITDA of INR 6,826 million, up 1.2% YoY. While EBITDA margins slightly declined to 28.6% from 29.5% in FY24 due to increased raw material and employee costs and the absence of Production Linked Incentive (PLI) benefits, they remain healthy and above peers, supported by the company's focus on niche, high-complexity APIs. Gross profit as a percentage of revenue reduced by 140 basis points.

The company maintains a strong net cash positive position, with cash on books increasing to INR 5,487 million in FY25 from INR 3,014 million in FY24. Return on Capital Employed (ROCE) stood at 23% in FY25, down from 27% in FY24. Net leverage remains strongly negative at -0.4x, indicating a robust balance sheet despite ongoing capex. Operating cash flow saw a slight decline to INR 3,915 million in FY25, and the working capital cycle extended to 192 days, primarily due to increased receivables from Glenmark Pharmaceuticals. However, free cash flow improved significantly to INR 2,253 million in FY25, aided by the decision not to pay dividends.

Alivus Life Sciences is undertaking significant planned capex of over INR 6,000 million for FY26-FY27 to expand its reactor capacity to 2,690 kl by 2028. This expansion aims to enhance backward integration and bolster EBITDA margins. The company's sustainable business profile, diversification into niche areas like high-potent APIs (HPAPIs), consistent R&D investment (3.4% of revenue in FY25), and its affiliation with the Nirma group further support its creditworthiness. Risks include regulatory and geopolitical factors, alongside foreign currency exposure managed through hedging. The Stable outlook reflects expectations of continued strong credit metrics.

Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, announced the appointment of M/s. Bhadresh Shah & Associates, a Peer Reviewed Firm of Practicing Company Secretaries, as its Secretarial Auditor. This appointment was approved by the shareholders at the company's 14th Annual General Meeting (AGM) held on September 8, 2025. The tenure for this appointment is for five consecutive financial years, commencing from April 01, 2025, and concluding on March 31, 2030. The company provided details as per SEBI Listing Regulations, including a brief profile of Mr. Bhadresh Shah, who has over sixteen years of experience in secretarial and legal matters, and whose firm offers comprehensive services in corporate laws and compliances to various companies. This is a routine compliance-related appointment, with no financial or operational performance data disclosed.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences) held its 14th Annual General Meeting (AGM) on September 8, 2025, entirely through Video Conferencing (VC)/Other Audio Visual Means (OAVM). The meeting concluded with the passage of all five resolutions set out in the notice, including the approval of the Audited Financial Statements for the Financial Year ended March 31, 2025, along with the Board and Auditors' reports. Shareholders also approved the declaration of a final dividend of Rs. 5 per equity share for the financial year ended March 31, 2025. Other resolutions passed included the re-appointment of a Director (Mr. Vinod Naik), ratification of the remuneration of the Cost Auditor (M/s. Kirit Mehta & Associates) for FY 2026, and the appointment of the Secretarial Auditor (M/s. Bhadresh Shah & Associates) for the current financial year. The Chairman presided over the meeting, and the Managing Director & CEO, Dr. Yasir Rawjee, presented the company's business overview, key milestones, and performance for FY 2024-25, also touching upon expansion plans to strengthen the API business. The voting results indicated overwhelming support for all resolutions, with minor dissenting votes observed in the appointment of a director and routine auditor appointments from the Public Non-Institutions category. Specific financial figures for FY2024-25 such as revenue, profit, or margins were discussed but are not detailed within this AGM proceedings document.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) held its 14th Annual General Meeting (AGM) on Monday, September 08, 2025, conducted via Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The meeting, which commenced at 3:00 p.m. IST and concluded at 4:48 p.m. IST, was presided over by Chairman Mr. Hiren Patel. Key attendees included Directors, Chairpersons of various committees (Audit, Nomination & Remuneration, Stakeholders Relationship), and representatives from the Company's statutory and secretarial auditors.

Shareholders participated through remote e-voting and e-voting during the AGM, facilitated by the National Securities Depository Limited (NSDL) system. All five ordinary resolutions presented in the AGM Notice were passed with the requisite majority.

The resolutions approved were:

1. Adoption of Audited Financial Statements: The audited financial statements for the Financial Year ended March 31, 2025, along with the reports of the Board and Auditors, were approved. This resolution garnered 99.9997% of the votes polled in favour.
2. Final Dividend Declaration: A final dividend of Rs. 5/- per equity share for the financial year ended March 31, 2025, was declared. Voting results showed 99.9997% in favour.
3. Director Re-appointment: Mr. Vinod Naik, who retired by rotation, was re-appointed as a Director. This resolution received 95.9359% of the votes polled in favour.
4. Ratification of Cost Auditor Remuneration: The remuneration payable to M/s. Kirit Mehta & Associates, the Cost Auditors for the Financial Year ending March 31, 2026, was ratified. This was passed with 99.9996% in favour.
5. Appointment of Secretarial Auditor: M/s. Bhadresh Shah & Associates was appointed as the Secretarial Auditor of the Company. This resolution also secured 99.9996% of the votes polled in favour.

The Annual Report for FY 2024-25, containing the AGM notice, was disseminated electronically to shareholders. The company confirmed that the statutory auditors' report and secretarial audit report had no qualifications. The news does not contain specific financial performance figures for the latest quarter or year, nor does it provide future outlook or guidance from management.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has issued a formal intimation regarding the change of its corporate office address. The company's new corporate office is now situated at Technopolis Knowledge Park, A wing, 4th Floor, Mahakali Caves Road, Andheri East, Mumbai – 400093. This marks a relocation from its previous office at 4th Floor, OIA House, 470 Cardinal Gracious Road, Andheri East, Mumbai – 400099. The notification, dated September 03, 2025, was sent to both the BSE Ltd. and the National Stock Exchange of India Ltd. for their records. This change is purely an administrative update concerning the company's operational base and does not pertain to financial performance, earnings, guidance, or any other material business development. The company continues its operations under the CIN L74900PN2011PLC139963. No financial figures or operational impact details were disclosed as part of this announcement.

Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, has issued a formal disclosure to the BSE Ltd. and the National Stock Exchange of India Ltd. regarding an upcoming interaction with investors and analysts. The company has scheduled a virtual one-on-one meeting with Sowilo Investment Managers for September 02, 2025. This engagement is in compliance with Regulation 30 and Para A of Part A of Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The disclosure also notes that the meeting schedule and mode may be subject to change due to unforeseen circumstances involving the investor, analyst, or the company. No specific financial results, performance updates, or forward-looking guidance were part of this announcement; it solely serves as an intimation of the meeting.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, has officially filed a disclosure with the stock exchanges (BSE and NSE) on August 21, 2025. The purpose of this filing is to inform stakeholders about an upcoming meeting with an investor/analyst. Specifically, the company representatives are scheduled to meet with Green Lantern Capital on August 26, 2025. The meeting will be conducted in person in Mumbai and is categorized as a 'One on One' interaction. This type of engagement is standard practice for listed entities to maintain transparent communication with the financial community, allowing for discussions on company performance, strategy, and market outlook. However, this specific disclosure does not contain any financial results, performance metrics, management guidance, or updates on orders, expansions, products, or regulatory matters. It solely serves as a notification of a scheduled meeting with a specific investor entity, highlighting the company's commitment to investor outreach under SEBI's LODR Regulations. The company has also included a disclaimer that the schedule and mode of the meeting might change due to exigencies.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has disclosed receiving an order from the Office of Commissioner of Customs NS II. The order, received on August 19, 2025, concerns alleged mis-classification of goods. The Addl. Commissioner of Customs has imposed a redemption fine of ₹3,00,00,000 under Section 125 of the Customs Act, 1962. Additionally, a penalty of ₹6,54,473/- for differential export incentive (MEIS) under Section 28(4) and/or 28AAA, along with applicable interest under Section 28AA, has been levied. Further penalties of ₹5,00,000 each have been imposed under Sections 114 (iii), 114 AA, and 114 AB of the Customs Act, 1962, totaling ₹15,00,000 in penalties. The company has stated that there is no material impact on its financial, operational, or other activities due to this penalty. Alivus Life Sciences also indicated that the order is appealable and they will assess their right to appeal.

Alivus Life Sciences Limited has published newspaper advertisements on August 15, 2025, informing stakeholders about its 14th Annual General Meeting (AGM). The AGM was scheduled to be held on August 8, 2025, through video conferencing and other audio-visual means. The company has confirmed the dispatch of the Notice of AGM and the Integrated Annual Report for the Financial Year 2024-25 to its shareholders. Furthermore, the advertisement provides details regarding the e-voting facility available to shareholders to cast their votes on the resolutions proposed at the AGM. This regulatory filing does not contain any financial performance data, management guidance, or operational updates.

Alivus Life Sciences Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2024-25. The report outlines the company's performance and commitments across Environmental, Social, and Governance (ESG) parameters.

Environmental Initiatives: The company reported increased energy consumption YoY, with significant efforts in energy efficiency and a shift towards renewable sources. Key initiatives include installing energy-efficient chillers, upgrading transformers, revamping plants, and optimizing compressor operations. Water withdrawal and consumption increased YoY, with robust wastewater management systems including ETPs and RO plants for reuse. Total waste generated increased, with a focus on recovery and recycling. GHG emissions, particularly Scope 1, saw a notable increase YoY, while Scope 2 decreased. The company aims for Carbon Neutrality by 2030 and Water Neutrality by 2027.

Social Initiatives: The report details employee statistics, including diversity and inclusion metrics, and comprehensive well-being programs like health insurance and wellness plans. For workers, safety measures and grievance mechanisms are in place. The company emphasizes human rights, providing training and adhering to policies against discrimination and forced labor. CSR activities focus on community development through projects in healthcare (Project Sampurna) and education (Project ViGyasa), with the company receiving an SHRM Award for Community Impact. Health and safety are prioritized, with ISO 45001 certification and various risk assessment processes.

Governance Initiatives: Alivus Life Sciences has numerous policies in place covering ESG principles. The Board of Directors and a dedicated ESG Committee oversee ESG matters. Stakeholder engagement is a key focus, with transparent communication channels established. The company is committed to regulatory compliance, including SEBI regulations and environmental laws, although it incurred a penalty from GPCB for temporary environmental non-compliance, which has been resolved.

Alivus Life Sciences Ltd has made its Annual Report filing in compliance with Regulation 34(1) of the Securities and Exchange Board of India (SEBI). This is a standard regulatory procedure for publicly listed companies. The annual report is a comprehensive document that usually includes audited financial statements, the Board of Directors' report, management's discussion and analysis (MD&A) detailing business performance, strategies, and outlook, corporate governance disclosures, and shareholder information. The filing itself confirms adherence to SEBI's listing obligations and disclosure requirements. No specific financial performance figures, comparative analysis, market guidance, or significant corporate events are detailed in this particular notification about the filing. Investors are advised to consult the actual annual report document for detailed financial information and strategic insights.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences) has issued a notice for its 14th Annual General Meeting (AGM), scheduled to be held on Monday, September 8, 2025, at 3:00 PM IST. The meeting will be conducted exclusively through Video Conferencing (VC) or Other Audio-Visual Means (OAVM), adhering to prevailing regulatory guidelines.

The primary business of the AGM includes the adoption of the Audited Financial Statements for the Financial Year ended March 31, 2025, along with the respective reports from the Board of Directors and Auditors. Shareholders will vote on the declaration of a final dividend of ₹5 per equity share for FY 2024-25. The record date for determining eligibility for this dividend is September 1, 2025.

Additionally, the AGM agenda covers the re-appointment of Mr. Vinod Naik as an Executive Director who retires by rotation. The meeting will also seek shareholder ratification for the remuneration payable to M/s. Kirit Mehta & Associates as Cost Auditors for FY 2025-26 and the appointment of M/s. Bhadresh Shah & Associates as Secretarial Auditor for a five-year term from FY 2025-26 to FY 2029-30. Comprehensive instructions for remote e-voting, which will be open from September 4 to September 7, 2025, and for attending the virtual meeting are provided.

Alivus Life Sciences Limited, previously known as Glenmark Life Sciences Limited, has issued a notification regarding its 14th Annual General Meeting (AGM). The AGM is scheduled to take place on Monday, September 08, 2025, commencing at 3:00 p.m. IST. The meeting will be conducted virtually, allowing shareholders to attend via Video Conferencing (VC) or Other Audio Visual Means (OAVM). The company has also provided details concerning the e-voting process and instructions for members to register their email addresses for communication purposes. This announcement is a routine procedural disclosure for the company.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has informed the stock exchanges about the upcoming 14th Annual General Meeting (AGM) scheduled for Monday, September 8, 2025, at 03:00 pm IST. The meeting will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM), adhering to SEBI and MCA guidelines. The company's board had previously recommended a final dividend of ₹5.00 per equity share of ₹2 face value for the financial year ended March 31, 2025. To determine the shareholders entitled to this dividend, the company has fixed Monday, September 1, 2025, as the 'Record Date'. If approved at the AGM, the dividend payment will commence on or after Friday, September 12, 2025, after deducting applicable taxes.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has issued an intimation regarding its 14th Annual General Meeting (AGM). The AGM is scheduled to be held on Monday, September 8, 2025, commencing at 03:00 PM IST. The meeting will be conducted entirely through Video Conferencing (VC) or Other Audio-Visual Means (OAVM), adhering to current regulations. The company has also fixed Monday, September 1, 2025, as the 'Record Date' for the purpose of determining the entitlement of shareholders to receive the final dividend recommended by the Board of Directors. The Board had previously recommended a final dividend of Rs 5.00 per equity share of Rs 2 each for the financial year ended March 31, 2025. This dividend is subject to the approval of shareholders at the AGM. If approved, the dividend payment will commence on or after Friday, September 12, 2025, after deduction of applicable taxes at source, to beneficial owners holding shares in dematerialized form or to members holding shares in physical form as of the close of business hours on the record date.

Alivus Life Sciences (formerly Glenmark Life Sciences) announced its Q1 FY26 results, with revenue from operations standing at INR 602 crore, marking a 2.2% year-on-year increase. This growth was primarily driven by the non-GPL business (+14.5% YoY), though offset by a 22% YoY decline in the GPL business due to inventory rationalization by the latter. The generic API business saw a consolidated moderate growth of 3% YoY. Gross profit grew by 10.2% YoY to INR 332 crore, leading to a gross margin of 55.1% (up 400 bps), attributed to rationalized input costs and operational efficiencies. EBITDA for the quarter was INR 181 crore, up 9.9% YoY, with EBITDA margins at 30.1% (up 210 bps), exceeding guidance. Profit after tax (PAT) stood at INR 122 crore with PAT margins at 20.2%. The company reported R&D expenditure of INR 21 crore (3.5% of sales). Capital expenditure for the quarter was INR 52 crore, and total capex for FY26 is planned at INR 600 crore, including a carryover of INR 190 crore. Alivus remains net debt-free, with cash and cash equivalents at INR 660 crore. Management reiterated its FY26 guidance of mid-teens volume growth and high single-digit revenue growth, expecting a stronger second half driven by GPL business recovery and CDMO project commercialization. Margins are expected to remain in the 28-30% band. Significant operational highlights include the Dahej facility receiving US FDA EIR with an NAI classification and the Ankleshwar facility also receiving EIR earlier this year. The Solapur facility is expected to commence operations in Q4 FY26. The company sees strong potential in its high-potent API pipeline and aims to grow its CDMO business to 12-15% of revenue in 4-5 years, focusing on the chemistry platform and flow chemistry investments.

Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, has issued a disclosure to the stock exchanges (BSE and NSE) regarding an upcoming meeting with investors and analysts. As per the intimation filed on August 4, 2025, the company's representatives will participate in an in-person, one-on-one meeting with Julius Baer on August 7, 2025, to be held in Mumbai. The company has noted that the schedule and mode of the meeting may be subject to change due to exigencies. This engagement is conducted under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, and is a routine interaction for disseminating company information to the financial community.

This news filing from Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited), dated August 02, 2025, is an intimation to the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) regarding the availability of the audio recording for their Q1 FY2025-26 Earnings Call. The company has uploaded the recording on its official website, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This allows investors and stakeholders to listen to the management's commentary, analysis of financial performance, outlook, and strategic discussions pertaining to the first quarter of the fiscal year 2025-26. The news itself does not contain the financial results or specific guidance points from the call, but rather confirms the accessibility of the discussion.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has filed a regulatory disclosure regarding an upcoming investor and analyst meeting. The meeting is scheduled for August 6, 2025, and will be held in person in Mumbai with Nine River Capital. This notification is in compliance with Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company also highlighted that the specified date and mode of the meeting are subject to potential changes due to unforeseen circumstances affecting the investor, analyst, or the company itself. This announcement is a standard procedural communication aimed at keeping the market informed about potential management interactions, but it does not contain any financial results, performance updates, guidance, or specific details about the topics to be discussed.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences) announced its Q1 FY26 financial results, presenting a revenue from operations of ₹6,018 million, marking a 2.2% year-on-year (YoY) increase, though down 7.4% quarter-on-quarter (QoQ). The company reported a significant YoY improvement in profitability, with EBITDA reaching ₹1,813 million (up 9.9% YoY) and EBITDA margins expanding by 210 basis points to 30.1%, driven by enhanced gross margins of 55.1% (up 400 bps YoY). Profit After Tax (PAT) was ₹1,215 million, a 9.0% YoY increase, with PAT margins improving to 20.2%. The Non-GPL business was a key growth driver, expanding by 14.5% YoY, while the GPL business saw a de-growth of 22.3% YoY due to customer inventory rationalization. Management provided an outlook for FY26, expecting high single-digit revenue growth with stronger momentum in the second half, and projected healthy EBITDA margins between 28-30%. The company generated ₹1,000 million in free cash flow during the quarter and continues to invest in capacity expansion, including its Solapur Greenfield project. Generic API revenues grew 3.0% YoY, while the CDMO business declined 15.3% YoY.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced its financial results for the first quarter ended June 30, 2025 (Q1FY26).

Performance Highlights:
• Revenue from operations for Q1FY26 was Rs. 6,018 Mn, marking a 2.2% year-on-year (YoY) growth.
• EBITDA grew by 9.9% YoY to Rs. 1,813 Mn.
• EBITDA margins improved significantly, reaching 30.1%, up by 210 basis points (bps) YoY.
• Gross Margins were reported at 55.1%, an increase of 400 bps YoY.
• Profit After Tax (PAT) for the quarter stood at Rs. 1,215 Mn, with PAT margins at 20.2%.
• The company generated a strong free cash flow of Rs. 1,000 Mn during the quarter.
• As of June 30, 2025, cash and cash equivalents (including short-term investments) stood at Rs. 6,604 Mn. The CFO also noted a debt-free balance sheet.

Outlook & Commentary:
• Dr. Yasir Rawjee, MD & CEO, stated that performance was driven by strong growth in the Non-GPL business, which expanded by 14.5% YoY, with contributions from India (Ex-GPL), Europe, ROW, LATAM, and Japan.
• Management guides for high single-digit revenue growth in FY26, expecting stronger momentum in the second half. Margins are projected to remain healthy in the 28–30% range.
• Tushar Mistry, CFO, reiterated that margins were well within the guided range and the healthy free cash flow strengthens the debt-free position.

Additional Highlights & Developments:
• The company continues DMF/CEP filings, reaching a cumulative total of 569 filings as of June 30, 2025.
• Five synthetic small molecules were added to the development grid in Q1FY26.
• The HP API portfolio comprises 26 APIs in the active grid, with nine validated, three in advanced development, and 14 in lab development.
• Capex update: Phase 1 construction for 200 KL capacity is underway at the Solapur facility.

Company Overview:
Alivus Life Sciences is a leading developer and manufacturer of high-value APIs in chronic therapeutic areas, also providing CDMO services. It operates four manufacturing facilities and supplies products globally. The company is listed on BSE and NSE.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has notified the stock exchanges about the allotment of equity shares under its 'Employee Stock Option Scheme, 2021'. The Nomination and Remuneration Committee of the company approved the allotment of 52,200 equity shares, each with a face value of Rs. 2, to eligible employees. This corporate action has led to an increase in the company's paid-up share capital. The total number of equity shares has increased from 12,26,29,148 to 12,26,81,348, consequently raising the paid-up capital from Rs. 24,52,58,296 to Rs. 24,53,62,696. This is a standard operational event for companies managing ESOPs and does not reflect changes in core business performance or outlook.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced its unaudited financial results for the first quarter ended June 30, 2025. The company reported revenue from operations of ₹6,018.46 million for Q1 FY25, which represents a 2.25% increase compared to ₹5,886.16 million in the same quarter last year (Q1 FY24). However, this is a 7.34% decrease from the ₹6,495.45 million reported in the previous quarter (Q4 FY25).

Profit After Tax (PAT) for Q1 FY25 stood at ₹1,215.35 million, an increase of 8.97% year-on-year from ₹1,114.83 million in Q1 FY24. Sequentially, PAT declined by 14.34% from ₹1,418.68 million in Q4 FY25.

Earnings Per Share (EPS) followed a similar trend, with basic EPS at ₹9.91 for Q1 FY25, up 8.90% year-on-year from ₹9.10 in Q1 FY24, but down 14.35% from ₹11.57 in Q4 FY25.

EBITDA for Q1 FY25 was ₹1,787.94 million, a growth of 8.84% YoY, with an EBITDA margin of 29.27%. This compares to ₹1,642.72 million (27.65% margin) in Q1 FY24 and ₹2,048.46 million (31.05% margin) in Q4 FY25.

The company's Board of Directors approved these results, which were reviewed by the Audit Committee and subsequently by the statutory auditors, Walker Chandiok & Co LLP. The auditors issued an unmodified conclusion on the financial results.

Alivus Life Sciences identified Active Pharmaceutical Ingredient (API) as its single reporting segment. The filing does not contain details on management guidance, outlook, or specific financial deep dives beyond the P&L statement figures. No information on new orders, expansions, penalties, or dividends/buybacks was provided.

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced its unaudited financial results for the first quarter ended June 30, 2025.

Performance:

• Revenue from Operations: ₹6,018.46 million for Q1 FY25, an increase of 2.25% compared to ₹5,886.16 million in Q1 FY24. Quarter-on-quarter, revenue declined by 7.34% from ₹6,495.45 million in Q4 FY25.
• Profit After Tax (PAT): The company reported a PAT of ₹1,215.35 million for Q1 FY25, up 8.92% from ₹1,114.83 million in Q1 FY24. QoQ, PAT decreased by 14.34% from ₹1,418.68 million in Q4 FY25.
• Margins: The PAT margin improved to 20.19% in Q1 FY25 from 18.94% in Q1 FY24. The EBITDA margin also showed improvement, rising to approximately 30.12% in Q1 FY25 from 28.03% in Q1 FY24.
• EPS: Basic Earnings Per Share (EPS) for the quarter was ₹9.91, compared to ₹9.10 in the same period last year, marking an 8.90% increase.

Financials:

• The company reported total income of ₹6,108.31 million for Q1 FY25. Total expenses were ₹4,478.50 million.
• Profit Before Tax (PBT) stood at ₹1,629.81 million, an increase of 8.48% YoY.
• Finance costs saw a significant jump, increasing by 244.02% YoY to ₹12.51 million.

Other Information:

• The company operates in a single segment: Active Pharmaceutical Ingredient (API).
• The results were reviewed by the Audit Committee and approved by the Board of Directors on August 1, 2025. The auditor, Walker Chandiok & Co. LLP, provided an unmodified conclusion.
• No management guidance, order book details, or information on buybacks/dividends were provided in this filing.

The results indicate positive year-on-year growth in revenue and profit, along with margin expansion, but show a sequential decline. There is no forward-looking commentary available from the company in this release.